Compositions and methods for treatment of pain and neurological disorders
Compounds binding to PAR1 and increasing β-arrestin activity provide effective pain relief and slow neurological disease progression with reduced side effects, addressing the limitations of current treatments for neuropathic pain and neurological disorders.
Patent Information
- Application Number
- PCT/US2026/027599
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for pain and neurological disorders, particularly neuropathic pain and conditions like diabetic neuropathy, chemotherapy-induced neuropathy, and Alzheimer's disease, lack efficacy and are associated with significant side effects, and there is a need for new compositions and methods that minimize harmful side effects and address neurodegeneration.
Administering a therapeutically effective amount of a compound that binds to protease-activated receptor 1 (PAR1) and increases β-arrestin activity to treat pain and neurological conditions, including neuropathic and inflammatory pain, and diseases such as traumatic brain injury and Alzheimer's disease, while minimizing abuse potential and cytotoxicity.
The compounds effectively reduce pain severity and slow the progression of neurological diseases, with minimal side effects and improved oral bioavailability, as assessed by numerical rating scales and functional independence measures.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000005_0001 
Figure IMGF000006_0001
Abstract
Description
[0001] ATTORNEY DOCKET NO: 51861-002W02
[0002] COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN AND NEUROLOGICAL DISORDERS
[0003] Background of the Invention
[0004] Pain and neurological conditions are major causes of disability for patients, and together, these indications create a substantial economic burden on the healthcare system. For pain, effective treatment options are lacking, and there is a significant need for efficacious treatments that minimize deleterious side effects, such as the development of dependency. Neuropathic pain, in particular, is a condition that is driven by nerve damage often caused by diabetes, physical injury, surgery, or chemotherapy. It is estimated that approximately 7-10% of people worldwide suffer from neuropathic pain. The current standard of care for managing neuropathic pain has changed little for decades and includes the anticonvulsants gabapentin or pregabalin, as well as certain antidepressants, including amitriptyline and duloxetine. These compounds frequently have limited efficacy and / or substantial side effects. The epidemic of diabetes and its neuropathic effects has also heightened the need for new medicines, and several of the most widely used chemotherapies cause irreversible neuropathy in a significant fraction of cancer patients. In addition, neurological disorders pose significant therapeutic challenges and may severely impact an individual’s quality of life, leading to physical, emotional, and cognitive impairments. Accordingly, there exists a need for new methods and compositions that can treat pain and neurological conditions while minimizing harmful side effects.
[0005] Summary of the Invention
[0006] The present disclosure features methods of treating pain in a patient (e.g., a human patient) in need thereof. The methods may include administering to the patient a therapeutically effective amount of a compound that exhibits the following activities: (i) binding to protease-activated receptor 1 (PAR1), and (ii) effectuating an increase in p-arrestin activity (as compared, e.g., to the activity of p-arrestin in the absence of the compound, such as in the presence of a vehicle control). The methods disclosed herein may be used to treat different classes of pain, including - but not limited to - neuropathic pain and inflammatory pain. The types of pain that may be treated by the interventions described herein include both chronic pain and acute pain.
[0007] Additionally, the compositions and methods of the disclosure can be used to treat patients suffering from a neurological disease. Particularly, the compositions and methods provided herein may be used to treat an underlying neurological condition, as well as to slow the progression of the same.
[0008] Compounds of the disclosure may exhibit a variety of advantageous features that position these interventions to uniquely address challenges faced by patients suffering from pain and / or neurodegeneration. For example, compounds of the disclosure may minimize abuse potential in comparison to existing analgesics. Further, compounds of the disclosure may exhibit oral bioavailability and minimal cytotoxicity, among other beneficial properties disclosed herein.
[0009] In a first aspect, the disclosure features a method of treating pain in a human patient in need thereof by administering to the patient a therapeutically effective amount of a compound that binds PAR1 and increases p-arrestin activity (as compared, e.g., to the activity of p-arrestin in the absence of the compound, such as in the presence of a vehicle control).
[0010] In some embodiments, the pain is neuropathic pain. In some embodiments, the neuropathic pain is caused or accompanied by physical injury. In some embodiments, the neuropathic pain is a result ofATTORNEY DOCKET NO: 51861-002W02
[0011] diabetic neuropathy. In some embodiments, the neuropathic pain is a result of chemotherapy-induced peripheral neuropathy (CIPN).
[0012] In some embodiments of any of the above aspects or embodiments of the disclosure, the pain is inflammatory pain. In some embodiments, the inflammatory pain is from physical injury.
[0013] In some embodiments of any of the above aspects or embodiments of the disclosure, the pain is chronic pain. In some embodiments of any of the above aspects or embodiments of the disclosure, the pain is acute pain.
[0014] In some embodiments, the patient is diagnosed as having a neurological disease.
[0015] In some embodiments, the neurological disease is selected from traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS, " Lou Gehrig's disease"), Parkinson's disease (PD), Huntington's disease (HD), Peri ventricular leukomalacia (PVL), Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, multiinfarct dementia, Pick's disease, primary lateral sclerosis, degenerative ataxias, spinal and spinobulbar muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, multisystem degeneration (Shy-Drager syndrome), familial dysautonomia (Riley-Day syndrome), subacute sclerosing panencephalitis, Sandhoff disease, cortical basal degeneration, primary progressive aphasia, familial spastic disease, Binswanger's disease, dementia (including all underlying etiologies of dementia), fibromyalgia (FM), post-herpetic neuralgia (PHN), trigeminal neuralgia (TGN), anesthesia dolorosa (AD), central pain due to multiple sclerosis (MS), focal nerve injury, peripheral nerve injury, and a neurological condition resulting from surgery or physical injury.
[0016] In some embodiments, the neurological disease is selected from traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), and a neurological condition resulting from surgery or physical injury.
[0017] In another aspect, the disclosure features a method of treating a neurological disease in a human patient in need thereof by administering to the patient a therapeutically effective amount of a compound that binds PAR1 and increases p-arrestin activity (as compared, e.g., to the activity of p-arrestin in the absence of the compound, such as in the presence of a vehicle control).
[0018] In another aspect, the disclosure features a method of preventing secondary injury from a neurological disease in a human patient in need thereof by administering to the patient a therapeutically effective amount of a compound that binds PAR1 and increases p-arrestin activity (as compared, e.g., to the activity of p-arrestin in the absence of the compound, such as in the presence of a vehicle control).
[0019] In another aspect, the disclosure features a method of slowing the progression of a neurological disease in a human patient in need thereof by administering to the patient a therapeutically effective amount of a compound that binds PAR1 and increases p-arrestin activity (as compared, e.g., to the activity of p-arrestin in the absence of the compound, such as in the presence of a vehicle control).
[0020] In some embodiments, the neurological disease is selected from traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS, " Lou Gehrig's disease"), Parkinson's disease (PD), Huntington's disease (HD), Peri ventricular leukomalacia (PVL), Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, multiinfarct dementia, Pick's disease, primary lateral sclerosis, degenerative ataxias, spinal and spinobulbarATTORNEY DOCKET NO: 51861-002W02
[0021] muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, multisystem degeneration (Shy-Drager syndrome), familial dysautonomia (Riley-Day syndrome), subacute sclerosing panencephalitis, Sandhoff disease, cortical basal degeneration, primary progressive aphasia, familial spastic disease, Binswanger's disease, dementia (including all underlying etiologies of dementia), fibromyalgia (FM), post-herpetic neuralgia (PHN), trigeminal neuralgia (TGN), anesthesia dolorosa (AD), central pain due to multiple sclerosis (MS), focal nerve injury, peripheral nerve injury, and a neurological condition resulting from surgery or physical injury.
[0022] In some embodiments, the neurological disease is selected from traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), and a neurological condition resulting from surgery or physical injury.
[0023] In some embodiments of any of the above aspects or embodiments of the disclosure, the compound is a parmodulin.
[0024] In some embodiments, the compound inhibits PAR1 -mediated Gq protein signaling. In some embodiments, the compound exhibits PAR1 agonist activity. In some embodiments, the compound does not exhibit PAR1 agonist activity.
[0025] In some embodiments, following administration of the compound to the patient, the patient’s pain is assessed as being less severe than: a) priorto the administration of the compound; or b) without administration of the compound (i.e., less severe than the pain experienced by a subject of comparable age, body mass index, and / or disease state, but that has not been administered the compound). In some embodiments, the assessment is made by way of the Numerical Rating Scale (NRS), the Neuropathic Scale (NPS), or the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS). In some embodiments, following administration of the compound to the patient, the patient experiences an increase in the time period during which the patient retains functional independence. In some embodiments, the increase is assessed by way of the Barthel Index (Bl), the modified Rankin Scale (mRS), or the Functional Independence Measure (FIM).
[0026] In some embodiments of any of the above aspects or embodiments of the disclosure, the compound is represented by any one of Formulae (l-IV):
[0027]
[0028] wherein each R1and R2is independently selected from the group consisting of absent, hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl;ATTORNEY DOCKET NO: 51861-002W02
[0029] each X1, X2, and X3is independently selected from the group consisting of a covalent bond, -[C(R10)(R11)]V-, -S-, -O-C(R12)=C(R13)-, -C(OR15)(R14)-, -N(R16)-, and -C(O)-; wherein v is 0, 1, 2, or 3;
[0030] each R10, R11, R12, R13, and R14is independently selected from the group consisting of covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; or, alternatively, two R10, R11, R12, R13, R14, R15, or R16, together with the atoms to which they are attached, and any intervening atoms, may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
[0031] X4is selected from the group consisting of -N(R15)-, -C(O)-, -C(OR16)-, -C(R10)-, and -C(R11)=C(R12)-;
[0032] each X5and X6is independently selected from the group consisting of a covalent bond, -NR15-, -O-, and -CR16R10-;
[0033] each G1and G2is independently selected from the group consisting of absent, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; and
[0034] t is 0, 1, 2, or 3,
[0035] or a pharmaceutically acceptable salt thereof.ATTORNEY DOCKET NO: 51861-002W02
[0036] In some embodiments, ring A is selected from the group consisting of:
[0037]
[0038] wherein each R100, R101, and R102is independently selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl, wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
[0039] In some embodiments, R1is selected from the group consisting of hydrogen and CH3. In some embodiments, R1is hydrogen. In some embodiments, R2is selected from the group consisting of hydrogen and CH3. In some embodiments, R2is hydrogen.ATTORNEY DOCKET NO: 51861-002W02
[0040] In some embodiments, G1is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl. In some embodiments, G1is selected from the group consisting of:
[0041]
[0042] wherein each X7and X8is independently selected from the group consisting from O, S, and NH; R100is selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
[0043] In some embodiments, G2is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl. In some embodiments, G2is selected from the group consisting of:
[0044]
[0045] wherein each R100and R101is independently selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.ATTORNEY DOCKET NO: 51861-002W02
[0046] In some embodiments, A and G2are optionally substituted aromatic groups. In some embodiments, G2is optionally substituted aliphatic or optionally substituted alkyl. In some embodiments, G2is optionally substituted aryl or optionally substituted heteroaryl.
[0047] In some embodiments, the disclosure features a compound represented by Formula (V):
[0048]
[0049] wherein each of m and y is independently selected from 0, 1, 2, 3, and 4;
[0050] wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein each R10and R11is independently selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; and
[0051] wherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,
[0052] or a pharmaceutically acceptable salt thereof.
[0053] In some embodiments, the disclosure features a compound represented by Formula (VI):
[0054]
[0055] wherein each of m and y is independently selected from 0, 1, 2, 3, and 4;
[0056] wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein each R10and R11is independently selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of aATTORNEY DOCKET NO: 51861-002W02
[0057] covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; and
[0058] wherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,
[0059] or a pharmaceutically acceptable salt thereof.
[0060] In some embodiments, the disclosure features a compound represented by Formula (VII):
[0061]
[0062] wherein y is selected from 0, 1, 2, 3, and 4;
[0063] wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein R10is selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; and
[0064] wherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,
[0065] or a pharmaceutically acceptable salt thereof.
[0066] In some embodiments, the disclosure features a compound represented by Formula (VIII):
[0067]
[0068] wherein G5is selected from the group consisting of S(O2)R18, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein R18is optionally substituted alkyl.
[0069] wherein R1is selected from the group consisting of absent, hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively, G5and R1, or R1and R11, together with the atoms to which they areATTORNEY DOCKET NO: 51861-002W02
[0070] attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
[0071] wherein each R10and R11is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
[0072] wherein X9is N or O, with the proviso that when X9is O, R1is absent; and
[0073] wherein each m and y is independently selected from the group consisting of 0, 1, 2, 3, and 4, or a pharmaceutically acceptable salt thereof.
[0074] In some embodiments, the disclosure features a compound represented by Formula (IX):
[0075]
[0076] wherein G5is selected from the group consisting of S(O2)R18, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein R18is optionally substituted alkyl.
[0077] wherein R1is selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively, G5and R1, or R1and R11, together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
[0078] wherein each R10and R11is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; and
[0079] wherein each m and y is independently selected from the group consisting of 0, 1, 2, 3, and 4, or a pharmaceutically acceptable salt thereof.
[0080] In some embodiments, the disclosure features a compound represented by Formula (X):
[0081]
[0082] wherein each R104and R105is independently optionally substituted alkyl; and,ATTORNEY DOCKET NO: 51861-002W02
[0083] R106is a halogen, OCH3, or OR107a; wherein R107ais optionally substituted alkyl,
[0084] or a pharmaceutically acceptable salt thereof.
[0085] In some embodiments, the compound is any one of the following compounds 1-156:
[0086]
[0087] ATTORNEY DOCKET NO: 51861-002W02
[0088]
[0089] ATTORNEY DOCKET NO: 51861-002W02
[0090]
[0091] ATTORNEY DOCKET NO: 51861-002W02
[0092]
[0093] ATTORNEY DOCKET NO: 51861-002W02
[0094]
[0095] or a pharmaceutically acceptable salt thereof.ATTORNEY DOCKET NO: 51861-002W02
[0096] In some embodiments of any of the above aspects or embodiments of the disclosure, the compound is represented by Formula (XI):
[0097]
[0098] wherein each R201and R204is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl;
[0099] each R202and R203is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR205a, NHR205a, NR205aR205b, SR205a, S(O2)R205a, C(O)OH, C(O)OR205a, C(O)NH2, C(O)NR205aR205b, C(O)NHR205a, CF3, CN, NO2, N3, OCF3, NHC(O)R205a, C(O)R205a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R205aand R205bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
[0100] or a pharmaceutically acceptable salt thereof.
[0101] In some embodiments, the compound is one of the following compounds 157-159:
[0102]
[0103] or a pharmaceutically acceptable salt thereof.
[0104] In some embodiments of any of the above aspects or embodiments of the disclosure, the compound is represented by Formula (XII):
[0105]
[0106] wherein each G3, G4, R300, and R301is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR302a, NHR302a, NR302aR302b, SR302a, S(O2)R302a, C(O)OH, C(O)OR302a, C(O)NH2, C(O)NR302aR302b, C(O)NHR302a, CF3, CN, NO2, N3, OCF3, NHC(O)R302a, C(O)R302a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R302aand R302bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substitutedATTORNEY DOCKET NO: 51861-002W02
[0107] heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl,
[0108] or a pharmaceutically acceptable salt thereof.
[0109] In some embodiments, the compound is one of the following compounds 160-163:
[0110]
[0111] 162 163
[0112] or a pharmaceutically acceptable salt thereof.
[0113] In some embodiments, the compound exhibits an EC50 of less than or equal to 10 pM in an assay that measures PAR1-mediated p-arrestin signaling (e.g., about 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 210 nM, 220 nM, 230 nM, 240 nM, 250 nM, 260, nM, 270 nM, 280 nM, 290 nM, 300 nM, 310 nM, 320 nM, 330 nM, 340 nM, 350 nM, 360 nM, 370 nM, 380 nM, 390 nM, 400 nM, 410 nM, 420 nM, 430 nM, 440 nM, 450 nM, 460, nM, 470 nM, 480 nM, 490 nM, 500 nM, 510 nM, 520 nM, 530 nM, 540 nM, 550 nM, 560 nM, 570 nM, 580 nM, 590 nM, 600 nM, 610 nM, 620 nM, 630 nM, 640 nM, 650 nM, 660 nM, 670 nM, 680 nM, 690 nM, 700 nM, 710 nM, 720 nM, 730 nM, 740 nM, 750 nM, 760 nM, 770 nM, 780 nM, 790 nM, 800 nM, 810 nM, 820 nM, 830 nM, 840 nM, 850 nM, 860 nM, 870 nM, 880 nM, 890 nM, 900 nM, 910 nM, 920 nM, 930 nM, 940 nM, 950 nM, 960 nM, 970 nM, 980 nM, 990 nM, 1 pM, 1.1 pM, 1.2 pM, 1.3 pM, 1.4 pM, 1.5 pM, 1.6 pM, 1.7 pM, 1.8 pM, 1.9 pM, 2 pM, 2.1 pM, 2.2 pM, 2.3 pM, 2.4 pM, 2.5 pM, 2.6 pM, 2.7 pM, 2.8 pM, 2.9 pM, 3 pM, 3.1 pM, 3.2 pM, 3.3 pM, 3.4 pM, 3.5 pM, 3.6 pM, 3.7 pM, 3.8 pM, 3.9 pM, 4 pM, 4.1 pM, 4.2 pM, 4.3 pM, 4.4 pM, 4.5 pM, 4.6 pM, 4.7 pM, 4.8 pM, 4.9 pM, 5 pM, 5.1 pM, 5.2 pM, 5.3 pM, 5.4 pM, 5.5 pM, 5.6 pM, 5.7 pM, 5.8 pM, 5.9 pM, 6 pM, 6.1 pM, 6.2 pM, 6.3 pM, 6.4 pM, 6.5 pM, 6.6 pM, 6.7 pM, 6.8 pM, 6.9 pM, 7 pM, 7.1 pM, 7.2 pM, 7.3 pM, 7.4 pM, 7.5 pM, 7.6 pM, 7.7 pM, 7.8 pM, 7.9 pM, 8 pM, 8.1 pM, 8.2 pM, 8.3 pM, 8.4 pM, 8.5 pM, 8.6 pM, 8.7 pM, 8.8 pM, 8.9 pM, 9 pM, 9.1 pM, 9.2 pM, 9.3 pM, 9.4 pM, 9.5 pM, 9.6 pM, 9.7 pM, 9.8 pM, 9.9 pM, or 10 pM).
[0114] In some embodiments, the compound exhibits an EC50 of less than or equal to 10 pM and an EC50 of greater than or equal to 100 nM (e.g., about 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 210 nM, 220 nM, 230 nM, 240 nM, 250 nM, 260, nM, 270 nM, 280 nM, 290 nM, 300 nM, 310 nM, 320 nM, 330 nM, 340 nM, 350 nM, 360 nM, 370 nM, 380 nM, 390 nM, 400 nM, 410 nM, 420 nM, 430 nM, 440 nM, 450 nM, 460, nM, 470 nM, 480 nM, 490 nM, 500 nM, 510 nM, 520 nM, 530 nM, 540 nM, 550 nM, 560 nM, 570 nM, 580 nM, 590 nM, 600 nM, 610 nM, 620 nM, 630 nM, 640 nM, 650 nM, 660 nM, 670 nM, 680 nM, 690 nM, 700 nM, 710 nM, 720 nM, 730 nM, 740 nM, 750 nM, 760 nM, 770 nM, 780 nM, 790 nM, 800 nM, 810 nM, 820 nM, 830 nM, 840 nM, 850 nM, 860 nM, 870 nM, 880 nM, 890 nM, 900 nM, 910 nM, 920 nM, 930 nM, 940 nM, 950 nM, 960 nM, 970 nM, 980 nM, 990 nM, 1 pM, 1.1 pM, 1.2 pM, 1.3 pM, 1.4 pM, 1.5 pM, 1.6 pM, 1.7 pM, 1.8 pM, 1.9 pM, 2 pM, 2.1 pM, 2.2 pM, 2.3 pM, 2.4 pM, 2.5 pM, 2.6 pM, 2.7 pM, 2.8 pM, 2.9 pM, 3 pM, 3.1 pM, 3.2 pM, 3.3 pM, 3.4 pM, 3.5 pM,ATTORNEY DOCKET NO: 51861-002W02
[0115] 3.6 pM, 3.7 pM, 3.8 pM, 3.9 pM, 4 pM, 4.1 pM, 4.2 pM, 4.3 pM, 4.4 pM, 4.5 pM, 4.6 pM, 4.7 pM, 4.8 pM, 4.9 pM, 5 pM, 5.1 pM, 5.2 pM, 5.3 pM, 5.4 pM, 5.5 pM, 5.6 pM, 5.7 pM, 5.8 pM, 5.9 pM, 6 pM, 6.1 pM, 6.2 pM, 6.3 pM, 6.4 pM, 6.5 pM, 6.6 pM, 6.7 pM, 6.8 pM, 6.9 pM, 7 pM, 7.1 pM, 7.2 pM, 7.3 pM, 7.4 pM, 7.5 pM, 7.6 pM, 7.7 pM, 7.8 pM, 7.9 pM, 8 pM, 8.1 pM, 8.2 pM, 8.3 pM, 8.4 pM, 8.5 pM, 8.6 pM, 8.7 pM, 8.8 pM, 8.9 pM, 9 pM, 9.1 pM, 9.2 pM, 9.3 pM, 9.4 pM, 9.5 pM, 9.6 pM, 9.7 pM, 9.8 pM, 9.9 pM, or 10 pM) in an assay that measures PAR1-mediated p-arrestin signaling.
[0116] In some embodiments, upon exposure to p-arrestin, the compound effectuates an increase in p-arrestin recruitment and / or signaling of greater than or equal to 1.1-fold (e.g., an increase in p-arrestin recruitment and / or signaling of about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.2-fold, 2.4-fold, 2.6-fold, 2.8-fold, 3-fold, 3.2-fold, 3.4-fold, 3.7-fold, 4-fold, 4.4-fold, 4.8-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, 10-fold, 11 -fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, 50-fold, or greater) as compared to the level of p-arrestin recruitment and / or signaling effectuated, e.g., by a vehicle or negative control.
[0117] In some embodiments, the compound exhibits an EC50 of greater than or equal to 100 pM in an assay that measures PAR2-mediated p-arrestin signaling (e.g., about 100 pM, 110 pM, 120 pM, 130 pM, 140 pM, 150 pM, 160 pM, 170 pM, 180 pM, 190 pM, 200 pM, 210 pM, 220 pM, 230 pM, 240 pM, 250 pM, 260, pM, 270 pM, 280 pM, 290 pM, 300 pM, 310 pM, 320 pM, 330 pM, 340 pM, 350 pM, 360 pM, 370 pM, 380 pM, 390 pM, 400 pM, 410 pM, 420 pM, 430 pM, 440 pM, 450 pM, 460, pM, 470 pM, 480 pM, 490 pM, 500 pM, 510 pM, 520 pM, 530 pM, 540 pM, 550 pM, 560 pM, 570 pM, 580 pM, 590 pM, 600 pM, 610 pM, 620 pM, 630 pM, 640 pM, 650 pM, 660 pM, 670 pM, 680 pM, 690 pM, 700 pM, 710 pM, 720 pM, 730 pM, 740 pM, 750 pM, 760 pM, 770 pM, 780 pM, 790 pM, 800 pM, 810 pM, 820 pM, 830 pM, 840 pM, 850 pM, 860 pM, 870 pM, 880 pM, 890 pM, or 900 pM, or more).
[0118] In some embodiments, the compound exhibits an EC50 of greater than or equal to 100 pM and an EC50 of less than or equal to 900 pM (e.g., about 100 pM, 110 pM, 120 pM, 130 pM, 140 pM, 150 pM, 160 pM, 170 pM, 180 pM, 190 pM, 200 pM, 210 pM, 220 pM, 230 pM, 240 pM, 250 pM, 260, pM, 270 pM, 280 pM, 290 pM, 300 pM, 310 pM, 320 pM, 330 pM, 340 pM, 350 pM, 360 pM, 370 pM, 380 pM, 390 pM, 400 pM, 410 pM, 420 pM, 430 pM, 440 pM, 450 pM, 460, pM, 470 pM, 480 pM, 490 pM, 500 pM, 510 pM, 520 pM, 530 pM, 540 pM, 550 pM, 560 pM, 570 pM, 580 pM, 590 pM, 600 pM, 610 pM, 620 pM, 630 pM, 640 pM, 650 pM, 660 pM, 670 pM, 680 pM, 690 pM, 700 pM, 710 pM, 720 pM, 730 pM, 740 pM, 750 pM, 760 pM, 770 pM, 780 pM, 790 pM, 800 pM, 810 pM, 820 pM, 830 pM, 840 pM, 850 pM, 860 pM, 870 pM, 880 pM, 890 pM, or 900 pM) in an assay that measures PAR2-mediated p-arrestin signaling.
[0119] In some embodiments, the compound exhibits an oral bioavailability of at least 20% (e.g., about 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%).
[0120] In some embodiments, upon administration of the compound to the patient, the compound may improve the integrity of the subject’s blood brain barrier (BBB), blood-spinal cord barrier (BSCB), or one or more of the subject’s blood-nerve barriers (BNBs). In some embodiments, upon administration of the compound to a subject (e.g., a non-human test subject), the compound attenuates pain response, forATTORNEY DOCKET NO: 51861-002W02
[0121] example, as measured by a formalin test, hot plate test, tail flick test, Hargreave’s test, acetone test, sensitivity to von Frey filaments, gait analysis, burrowing behavior analysis, and / or Randall-Selitto test. In some embodiments, upon administration of the compound to the patient, the compound inhibits endothelial cell retraction.
[0122] In another aspect, the disclosure features a pharmaceutical composition containing a compound of any of the foregoing aspects or embodiments (e.g., a compound of any one of Formulae (l-XII)) and a pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, the pharmaceutical composition is for use in the treatment of pain or a neurological disorder, for example, in a patient (e.g., human patient) diagnosed with a condition or disease described above.
[0123] In some embodiments of any of the above aspects or embodiments of the disclosure, the therapeutically effective amount of a parmodulin is administered to the subject intravenously, intraperitoneally, subcutaneously, retro-orbitally, inhaled, topically, or orally, among other routes of administration described herein.
[0124] In another aspect, the disclosure features a kit containing a compound described herein (e.g., a parmodulin, such as a parmodulin set forth above). In some embodiments, the kit includes a package insert that instructs a user of the kit to administer the compound to a patient. In some embodiments, the patient is suffering from pain. In some embodiments, the pain is neuropathic pain. In some embodiments, the neuropathic pain is from physical injury. In some embodiments, the pain is a result of diabetic neuropathy. In some embodiments, the pain is a result of CIPN. In some embodiments, the pain is inflammatory pain. In some embodiments, the inflammatory pain is from physical injury. In some embodiments, the pain is chronic pain. In some embodiments, the pain is acute pain. In some embodiments, the pain is a result of a neurological disease.
[0125] In some embodiments, the compound within the kit is a parmodulin, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is represented by any one of Formulae (I-XII), ora pharmaceutically acceptable salt thereof.
[0126] In some embodiments, the package insert instructs a user of the kit to administer the compound to a patient diagnosed with a neurological disease, such as a neurological disease selected from traumatic brain injury, diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, Peri ventricular leukomalacia, Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy, bulbar and pseudobulbar palsy, multi-infarct dementia, Pick's disease, primary lateral sclerosis, degenerative ataxias, spinal and spinobulbar muscular atrophy, familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, multisystem degeneration, familial dysautonomia, subacute sclerosing panencephalitis, Sandhoff disease, cortical basal degeneration, primary progressive aphasia, familial spastic disease, Binswanger's disease, dementia, and a neurological condition resulting from surgery or physical injury. In some embodiments, the patient is diagnosed as having a neurological disease selected from traumatic brain injury, diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease, and a neurological condition resulting from surgery or physical injury.ATTORNEY DOCKET NO: 51861-002W02
[0127] Brief Description of the Figures
[0128] FIG. 1 is a schematic illustration of a parmodulin-PAR1 signaling pathway, indicating biased signaling towards p-arrestin effectuated by the parmodulin.
[0129] FIGS. 2A and 2B show the results of an exemplary PAR1 -p-arrestin assay using fluorescent Borealis p-arrestin-2 biosensor. Briefly, HEK 293T cells in 384 well plates were transfected with PAR1 and the Borealis p-arrestin-2 biosensor, then treated with different concentrations of the ligand of interest and the EC20 (160 nM) of the PAR1 agonist TFLLR-NH2. Activation of the p-arrestin-2 biosensor was quantified by its decrease in fluorescence at 509 nm upon activation. FIG. 2A: Vorapaxar inhibits PAR1-driven p-arrestin-2 recruitment. FIG. 2B: The parmodulin, compound 45, increases PAR1 -driven p-arrestin recruitment. The measurement of PAR1 -p-arrestin activity was made as described in Example 1 below. NFU = Normalized fluorescence units. FIG. 2C shows the results of exemplary PATHHUNTER™ PAR1 -p-arrestin assays, commercially available from Eurofins DiscoverX. Briefly, CHO-K1 epithelial cells stably expressing modified versions of PAR1 and p-arrestin containing complementary portions of a p-galactosidase enzyme were cultured in 384 well plates. The cells were incubated with ligands for 15 min., then treated with 20% effective concentration (EC20) of the PAR1 agonist TFLLR-NH2 for 2 h before addition of reagent cocktail (including luminescent p-galactosidase substrate) and measurement by plate reader.
[0130] FIG. 3 shows that exemplary parmodulins inhibit endothelial cell retraction, indicating the ability of compounds in this class to augment blood brain barrier (BBB) integrity. Briefly, EA.hy926 endothelial cells were cultured and treated with a range of parmodulins (10 pM) or vehicle before treatment with thrombin (10 nM) for 30 min. Intercellular gap formation (red areas) was visualized by F-actin staining (phalloidin, green; scale bar = 100 pm), and gap areas were quantified (5 images from each of 3 replicates) with Imaged in an automated fashion. Images of controls and compound 45 treatment are shown.
[0131] FIG. 4 shows the results of an experiment evaluating the effects of a compound of the disclosure on pain in a rat model. Briefly, Sprague-Dawley rats were divided into four groups (4 male, 4 female in each group) and subsequently underwent spared nerve injury surgery or sham surgery. Rats then received 7 daily i.p. doses of vehicle (90:10 PEG 400 (w / 2% w / v Tween 80): PBS; 1 mL / kg), or compound 45 (10 mg / kg) in vehicle. Rear paw withdrawal thresholds were measured on Day 9 (2 days after the last dose) with a Randall-Selitto analgesiometer on the side of the surgery (ipsilateral), and also the opposite (uninjured, contralateral) paw. Data were compared by 2-way ANOVA (**** p<0.0001).
[0132] Detailed Description of the Invention
[0133] The present disclosure features methods and compositions for treating pain in a patient, such as a patient suffering from neuropathic pain. In a non-limiting example, the patient may be administered a compound of the disclosure to alleviate physical suffering or discomfort. This discomfort may be caused by an underlying neurological disorder. Exemplary qualitative and quantitative scores that can be used to evaluate a patient and determine whether the patient is responding to pain treatment include, without limitation, pain scales such as the Numerical Rating Score (NRS), the Neuropathic Scale (NPS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
[0134] Additionally, the compositions and methods of the disclosure can be used to treat patients suffering from a neurological disease. The present disclosure additionally features methods and compositions for treating a secondary injury that results from a patient’s physiological response to aATTORNEY DOCKET NO: 51861-002W02
[0135] primary trauma to the nervous system. Secondary injury can continue to occur for hours to weeks following the primary injury. Primary injury may be caused by trauma, including but not limited to, from traumatic brain injury (TBI), spinal cord injury, surgery, physical injury, or chemotherapy.
[0136] The present disclosure additionally features methods and compositions for slowing the progression of a neurological disease in a human patient in need thereof, such as a patient suffering from a neurodegenerative disease. Accordingly, the patient may be administered a compound of the disclosure to provide a neuroprotective effect, as measured by the compound’s ability to mitigate further symptom progression or alleviate symptoms associated with neurological disorder or neurological disease.
[0137] Exemplary neuroprotective benefits include, without limitation, prolonging the period that patients retain functional independence in activities of daily living, reduction in neuronal damage biomarkers (e.g., matrix metalloproteinases), reduction in rate of severe adverse events (SAEs), reduction in all-cause mortality, and improved cognitive or neurological function.
[0138] The present disclosure is based, at least in part, on the surprising observation that administration of a parmodulin, such as a compound of any one of Formulae (l-XII) (e.g., / V-[3-(2-bromobenzamido)phenyl]-1,3-oxazole-5-carboxamide (45), or a pharmaceutically acceptable salt thereof), may effectuate a reduction in pain, as well as various cytoprotective effects. In particular, and unexpectedly, compounds of the disclosure may sustain the reduction in pain for one or more days even after administration of the compound has ceased. Without being limited by mechanism, these beneficial properties may be attributed to the ability of compounds of the disclosure to bind protease-activated receptor 1 (PAR1) and concomitantly increase the activity of p-arrestin.
[0139] Particularly, PAR1 can mediate pro- or anti-inflammatory effects depending on its ligand(s) and additional complexing proteins, as is shown in FIG. 1. For example, proteolytic cleavage of the N-terminus of PAR1 by certain proteases reveals a tethered ligand that self-activates PAR1. Cleavage at Arg41 by thrombin on PAR1 of endothelial cells leads to endothelial PAR1-Gq signaling. This, in turn, increases local levels of apoptosis and coagulation. Conversely, alternative cleavage of PAR1 by activated protein C (APC) at Arg46 can provide cytoprotective and endothelial barrier-protective effects through an increase of p-arrestin activity, which may be relevant to the integrity of barriers between the blood and components of the nervous system, including the blood brain barrier (BBB), blood spinal cord barrier (BSCB), and blood-nerve barriers (BNBs). Alternatively, as observed with compounds in this disclosure, PAR1 can be treated with a suitable positive allosteric modulator (referred to herein as a “parmodulin”), resulting in an increase in PAR1-mediated p-arrestin signaling. The compounds of the disclosure represent a new class of PAR1 -targeting drugs that promote cytoprotective signaling in situations that normally increase PAR1 -driven cytotoxicity. Without being limited by mechanism, this cytoprotective activity, as well as the augmenting of BBB, BSCB, and BNB integrity, represent modes by which the compounds of the disclosure may alleviate pain and / or treat neurological disorders.
[0140] Existing methods and compositions for pain management, such as opiates, often have deleterious side effects - chief among these is abuse potential. Compounds of the disclosure represent a beneficial class of analgesic drugs that may minimize abuse potential, for example, by virtue of their rapid clearance post-administration. Other exemplary properties exhibited by compounds of the disclosure include features that render the compounds suitable for oral administration (e.g., suitability for chronic oral administration), robust bioavailability, and minimal off-target effects.ATTORNEY DOCKET NO: 51861-002W02
[0141] The sections that follow provide a detailed description of the various examples of compounds that may be used to treat pain and / or neurological disorders, as well as exemplary methods for administering interventions of the disclosure to patients in need of pain management.
[0142] Definitions
[0143] As used herein, the term “about” refers to a value that is within 10% above or below the value being described. For example, the term “about 10 pM” indicates a range from 9 pM to 11 pM.
[0144] As used herein, the terms "bind," “binds,” “binding,” and the like refer to a noncovalent interaction between two substances (for example, a noncovalent interaction between a compound of the disclosure (e.g., a parmodulin) and a target protein (e.g., PAR1)). The interaction may be one of high affinity between the two substances. In some embodiments, the interaction between the two substances may be one that is characterized by an EC50 of a first substance (e.g., a parmodulin) with respect to the biological activity of a second substance (e.g., a protein binding partner thereof, such as PAR1), of, for example, less than or equal to 10 pM (e.g., about 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 210 nM, 220 nM, 230 nM, 240 nM, 250 nM, 260, nM, 270 nM, 280 nM, 290 nM, 300 nM, 310 nM, 320 nM, 330 nM, 340 nM, 350 nM, 360 nM, 370 nM, 380 nM, 390 nM, 400 nM, 410 nM, 420 nM, 430 nM, 440 nM, 450 nM, 460 nM, 470 nM, 480 nM, 490 nM, 500 nM, 510 nM, 520 nM, 530 nM, 540 nM, 550 nM, 560 nM, 570 nM, 580 nM, 590 nM, 600 nM, 610 nM, 620 nM, 630 nM, 640 nM, 650 nM, 660 nM, 670 nM, 680 nM, 690 nM, 700 nM, 710 nM, 720 nM, 730 nM, 740 nM, 750 nM, 760 nM, 770 nM, 780 nM, 790 nM, 800 nM, 810 nM, 820 nM, 830 nM, 840 nM, 850 nM, 860 nM, 870 nM, 880 nM, 890 nM, 900 nM, 910 nM, 920 nM, 930 nM, 940 nM, 950 nM, 960 nM, 970 nM, 980 nM, 990 nM, 1 pM, 1.1 pM, 1.2 pM, 1.3 pM, 1.4 pM, 1.5 pM, 1.6 pM, 1.7 pM, 1.8 pM, 1.9 pM, 2 pM, 2.1 pM, 2.2 pM, 2.3 pM, 2.4 pM, 2.5 pM, 2.6 pM, 2.7 pM, 2.8 pM, 2.9 pM, 3 pM, 3.1 pM, 3.2 pM, 3.3 pM, 3.4 pM, 3.5 pM, 3.6 pM, 3.7 pM, 3.8 pM, 3.9 pM, 4 pM, 4.1 pM, 4.2 pM, 4.3 pM, 4.4 pM, 4.5 pM, 4.6 pM, 4.7 pM, 4.8 pM, 4.9 pM, 5 pM, 5.1 pM, 5.2 pM, 5.3 pM, 5.4 pM, 5.5 pM, 5.6 pM, 5.7 pM, 5.8 pM, 5.9 pM, 6 pM, 6.1 pM, 6.2 pM, 6.3 pM, 6.4 pM, 6.5 pM, 6.6 pM, 6.7 pM, 6.8 pM, 6.9 pM, 7 pM, 7.1 pM, 7.2 pM, 7.3 pM, 7.4 pM, 7.5 pM, 7.6 pM, 7.7 pM, 7.8 pM, 7.9 pM, 8 pM, 8.1 pM, 8.2 pM, 8.3 pM, 8.4 pM, 8.5 pM, 8.6 pM, 8.7 pM, 8.8 pM, 8.9 pM, 9 pM, 9.1 pM, 9.2 pM, 9.3 pM, 9.4 pM, 9.5 pM, 9.6 pM, 9.7 pM, 9.8 pM, 9.9 pM, or 10 pM) in an assay that measures a biological activity of the second substance (e.g., PAR1-mediated p-arrestin signaling). In some embodiments, the interaction between the two substances may be one that is characterized by the ability of the first substance to effectuate an increase in the biological activity of the second substance relative, e.g., to the biological activity of the second substance in the absence of the first substance and / or in the presence of a negative (e.g., vehicle) control. In the context of a parmodulin of the disclosure and PAR1, the interaction may be one that is characterized by an ability of the parmodulin to effectuate an increase in, e.g., PAR1-mediated p-arrestin recruitment and / or signaling of greater than or equal to 1.1-fold (e.g., an increase in PAR1-mediated p-arrestin recruitment and / or signaling of about 1.1 -fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.2-fold, 2.4-fold, 2.6-fold, 2.8-fold, 3-fold, 3.2-fold, 3.4-fold, 3.7-fold, 4-fold, 4.4-fold, 4.8-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, 50-fold, or greater) as compared to the level of p-arrestin recruitment and / or signaling effectuated, e.g., by a vehicle or negative control.ATTORNEY DOCKET NO: 51861-002W02
[0145] As used herein, the term “compound” refers to a small-molecule therapeutic agent. As will be understood by one of skill in the art, small molecules are typically low-molecular weight organic molecules (e.g., of less than or equal to about 1,000 Da in molecular mass). Small molecules may have one or more amide bonds therein, but it is to be understood that the term “compound” does not refer to a protein or to a peptide fragment of a larger protein.
[0146] As used herein, the terms “protease-activated receptors” and “PARs” refer to a subfamily of four related G protein-coupled receptors that are activated by proteolytic cleavage of their extracellular domain.
[0147] As used herein, the term “parmodulin” refers to a biased, allosteric ligand of PAR1, which selectively augments PAR1 -driven p-arrestin activity by acting as a positive modulator of PAR1. In some embodiments, a parmodulin may also exhibit a direct agonist effect on PAR1 - such parmodulins are referred to herein as “ago-PAMs.” In other embodiments, parmodulins are not direct PAR1 agonists. Unlike vorapaxar- an FDA-approved antiplatelet PAR1 antagonist - and other known PAR1 antagonists, upon binding to PAR1, a parmodulin increases p-arrestin recruitment and may simultaneously inhibit PAR1 -driven Gq signaling. An exemplary method to measure PAR1 -driven p-arrestin activity (for example, in human embryonic kidney (HEK 293T) cells or Chinese hamster ovary (CHO) cells expressing PAR1 or modified versions of PAR1, stably or transiently), involves measuring p-arrestin-2 responses to the PAR1 agonist TFLLR-NH2 (at EC20). For example, commercial assays measure p-arrestin recruitment to PAR1 by using enzyme complementation technology (e.g., PATHHUNTER™, Eurofins DiscoverX catalog# 93-0278E2CP0M), as described in Wehrman, T. S., Casipit, C. L., Gewertz, N. M. & Blau, H. M. Enzymatic detection of protein translocation. Nature Methods 2, 521-527 (2005), or with a p-arrestin biosensor possessing a fluorescent tag that has different optical properties upon binding to PAR1 (e.g., Montana Molecular catalog# D2170G), as described in Hoare, S. R. J., etal. A kinetic method for measuring agonist efficacy and ligand bias using high resolution biosensors and a kinetic data analysis framework. Scientific Reports 10, (2020). By taking measurements prior to and after agonist addition, compounds can be characterized as PAR1 -p-arrestin agonists, inverse agonists, antagonists, negative allosteric modulators, or positive allosteric modulators. For example, in some embodiments, compounds at a concentration of 10 pM that give a 3-fold increase in PAR1 -driven p-arrestin recruitment using the EC20 of a PAR1 agonist (such as TFLLR-NH2) may be considered as meeting the criteria for positive allosteric modulators of PAR1 -driven β-arrestin activity.
[0148] An additional assay may be used to confirm that p-arrestin activity is selectively dependent on PAR1 and not driven by the closely related receptor PAR2. An exemplary method for evaluating the same involves measuring PAR2-driven p-arrestin activity due to the PAR2 agonist 2-furoyl-LIGRLO in PAR2 assays analogous to those described above. The PAR2-driven p-arrestin activity assay kit has been validated and is available from Eurofins DiscoverX (catalog# 93-0235E1CP0M) or Montana Molecular (#D2090G). In some embodiments, compounds with EC50 < 10 pM (e.g., about 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 210 nM, 220 nM, 230 nM, 240 nM, 250 nM, 260, nM, 270 nM, 280 nM, 290 nM, 300 nM, 310 nM, 320 nM, 330 nM, 340 nM, 350 nM, 360 nM, 370 nM, 380 nM, 390 nM, 400 nM, 410 nM, 420 nM, 430 nM, 440 nM, 450 nM, 460, nM, 470 nM, 480 nM, 490 nM, 500 nM, 510 nM, 520 nM, 530 nM, 540 nM, 550 nM, 560 nM, 570 nM, 580 nM, 590 nM, 600 nM, 610 nM, 620 nM, 630 nM, 640 nM, 650 nM, 660 nM, 670 nM, 680 nM, 690 nM, 700 nM, 710 nM, 720 nM, 730 nM, 740 nM, 750 nM, 760 nM, 770 nM, 780 nM, 790 nM, 800 nM, 810 nM, 820 nM, 830 nM, 840 nM,ATTORNEY DOCKET NO: 51861-002W02
[0149] 850 nM, 860 nM, 870 nM, 880 nM, 890 nM, 900 nM, 910 nM, 920 nM, 930 nM, 940 nM, 950 nM, 960 nM, 970 nM, 980 nM, 990 nM, 1 pM, 1.1 pM, 1.2 pM, 1.3 pM, 1.4 pM, 1.5 pM, 1.6 pM, 1.7 pM, 1.8 pM, 1.9 pM, 2 pM, 2.1 pM, 2.2 pM, 2.3 pM, 2.4 pM, 2.5 pM, 2.6 pM, 2.7 pM, 2.8 pM, 2.9 pM, 3 pM, 3.1 pM, 3.2 pM, 3.3 pM, 3.4 pM, 3.5 pM, 3.6 pM, 3.7 pM, 3.8 pM, 3.9 pM, 4 pM, 4.1 pM, 4.2 pM, 4.3 pM, 4.4 pM, 4.5 pM, 4.6 pM, 4.7 pM, 4.8 pM, 4.9 pM, 5 pM, 5.1 pM, 5.2 pM, 5.3 pM, 5.4 pM, 5.5 pM, 5.6 pM, 5.7 pM, 5.8 pM, 5.9 pM, 6 pM, 6.1 pM, 6.2 pM, 6.3 pM, 6.4 pM, 6.5 pM, 6.6 pM, 6.7 pM, 6.8 pM, 6.9 pM, 7 pM, 7.1 pM, 7.2 pM, 7.3 pM, 7.4 pM, 7.5 pM, 7.6 pM, 7.7 pM, 7.8 pM, 7.9 pM, 8 pM, 8.1 pM, 8.2 pM, 8.3 pM, 8.4 pM, 8.5 pM, 8.6 pM, 8.7 pM, 8.8 pM, 8.9 pM, 9 pM, 9.1 pM, 9.2 pM, 9.3 pM, 9.4 pM, 9.5 pM, 9.6 pM, 9.7 pM, 9.8 pM, 9.9 pM, or 10 pM) in the PAR1 -driven p-arrestin activity assay and an EC50 > 100 pM (e.g., about 100 pM, 110 pM, 120 pM, 130 pM, 140 pM, 150 pM, 160 pM, 170 pM, 180 pM, 190 pM, 200 pM, 210 pM, 220 pM, 230 pM, 240 pM, 250 pM, 260, pM, 270 pM, 280 pM, 290 pM, 300 pM, 310 pM, 320 pM, 330 pM, 340 pM, 350 pM, 360 pM, 370 pM, 380 pM, 390 pM, 400 pM, 410 pM, 420 pM, 430 pM, 440 pM, 450 pM, 460, pM, 470 pM, 480 pM, 490 pM, 500 pM, 510 pM, 520 pM, 530 pM, 540 pM, 550 pM, 560 pM, 570 pM, 580 pM, 590 pM, 600 pM, 610 pM, 620 pM, 630 pM, 640 pM, 650 pM, 660 pM, 670 pM, 680 pM, 690 pM, 700 pM, 710 pM, 720 pM, 730 pM, 740 pM, 750 pM, 760 pM, 770 pM, 780 pM, 790 pM, 800 pM, 810 pM, 820 pM, 830 pM, 840 pM, 850 pM, 860 pM, 870 pM, 880 pM, 890 pM, or 900 pM) in the PAR2-driven p-arrestin activity assay will be considered PAR1 -selective agonists of β-arrestin activity.
[0150] Inhibition of PAR1-driven Gq signaling can be measured using several published and / or commercial methods with numerous cell types from different species. These use a PAR1 agonist, such as SFLLRN-NH2 or TFLLRN-NH2, with cells that express PAR1, such as platelets, endothelial cells (including EA.hy926, HUVEC), fibroblasts (3T3), or epithelial cells (HEK 293), which may transiently or stably express PAR1. Gq signaling can be measured from its downstream effects in these PAR1 -expressing cells, such as increases in calcium mobilization, as described in DeRousse, J. T. & Dockendorff, C.
[0151] Characterizing Modulators of Protease-activated Receptors with a Calcium Mobilization Assay Using a Plate Reader. Journal of Visualized Experiments (2024), IP1, or platelet P-selectin release, the methods of which are described in Dockendorff, C. etal. Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Med Chem Lett 3, 232-237 (2012). For example, in some embodiments, compounds at a concentration of 10 pM that inhibit PAR1 -driven calcium mobilization (using the PAR1 agonist SFLLRN-NH2 at 5 pM) by at least 50% may be considered as meeting the criteria for inhibitors (antagonists) of PAR1 -driven Gq activity.
[0152] As used herein, the terms “treat” or “treatment” refer to therapeutic treatment, in which the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as pain caused by neurological disorder or neurological disease. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, such as slowing or reversing neurological disease progression, mitigation of secondary injury resulting from neurological disorder or disease, or a reduction of pain.
[0153] As used herein, the term “neuroprotective” refers to interventions that prevent or limit neurological disease progression or damage from secondary injuries. Without being limited by mechanism, neuroprotective compounds may function by counteracting the detrimental physiological and molecular events that result in irreversible neurological damage. Exemplary evidence that a compound has a neuroprotective effect can be demonstrated in vivo (e.g., in any of the neuropathic pain models disclosed herein or known in the art) or in vitro (e.g., in any of the in vitro neuroprotection assays described herein or known in the art). In some embodiments, in vitro neuroprotection assays involve exposing neural cellsATTORNEY DOCKET NO: 51861-002W02
[0154] (e.g., neurons and glial cells) to a variety of chemical agents (e.g., thrombin or a chemotoxic agent) and / or conditions (e.g., physical stress or hyperglycemic conditions) to simulate a range of neurological conditions. Exemplary in vitro evidence that a compound is neuroprotective may be evidenced by one or more of the following: (1) increased neuronal cell viability, (2) decreased neurite fragmentation, (3) decreased injury markers under conditions of excitotoxicity (elevated concentrations of glutamate or NMDA), (4) decreased signs of physical injury, (5) decreased signs of chemical injury, (6) decreased signs of cytokine injury, or (7) decreased signs of neurotoxic peptide injury. Neuroprotective compounds taken following a primary neurological injury may also limit the damage from or prevent secondary injury.
[0155] As used herein, the term “secondary injury” refers to the damage that results from patient’s physiological response to an initial, also known as primary, trauma to the nervous system. Secondary injury can continue to occur for hours or weeks following the primary injury. Primary injury may be caused by trauma, for example, from ischemic stroke, traumatic brain injury (TBI), spinal cord injury, surgery, physical injury, or chemotherapy, among other sources. More generally, clinical results demonstrating neuroprotection include, but are not limited to, mitigating further symptom progression or alleviation of symptoms associated with neurological disorder or neurological disease. Specific examples of neuroprotective benefits that may be effectuated by the compounds of the disclosure include, without limitation, (i) prolonging the period during which patients retain functional independence in activities of daily living, (ii) reduction in neuronal damage biomarkers (e.g., matrix metalloproteinases), (iii) reduction in rate of severe adverse events (SAEs), (iv) reduction in all-cause mortality, and (v) improved cognitive or neurological function. For acute neurological injury that cause ischemia, for example, resulting from a TBI, additional neuroprotective benefits may include (i) mitigation of growth or reduction in volume of ischemic lesion and / or infarct, or (ii) lower subsequent hemorrhage rate. Exemplary methods used to measure functional independence in activities of daily living include the Barthel Index (Bl), the modified Rankin Scale (mRS), and the Functional Independence Measure (FIM), are described in detail, e.g., in Duncan et al., Outcome Measures in Acute Stroke Trials. Stroke 31, 1429-1438 (2000), the disclosure of which is incorporated herein by reference.
[0156] As used herein, “neurological disease” or “neurological disorder” refers to a disease or disorder that affects nerves in the brain, spinal cord, or the rest of the human body. A neurological disorder can be caused by electrical, structural, or biochemical abnormalities in neurons, among other causes. A neurological disorder may be caused by disease or injury, such as a result of ischemic stroke, traumatic brain injury (TBI), or as a consequence of diabetes, surgery, or physical injury. As used herein, neurological disorders include neurodegenerative disorders.
[0157] As used herein, “neurodegenerative disease” and “neurodegenerative disorder” are used interchangeably to refer to a disease that is characterized by neural cell death as a pathological state. A neurodegenerative disease or disorder may exhibit chronic neurodegeneration, e.g., slow, progressive neural cell death over a period of several years, or acute neurodegeneration, e.g., sudden onset or neural cell death. The foregoing diseases may be caused, for example, by the deterioration of cell and tissue components of the nervous system. Non-limiting examples of neurodegenerative disorders include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), spinal leukodystrophies, periventricular leukomalacia (PVL), amyotrophic lateral sclerosis (ALS, " Lou Gehrig's disease"), ALS-Parkinson's-Dementia complex of Guam, Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy,ATTORNEY DOCKET NO: 51861-002W02
[0158] diabetic retinopathy, multi-infarct dementia, macular degeneration, Pick's disease, diffuse Lewy body disease, prion diseases such as Creutzfeldt- Jakob, Gerstmann-Straussler-Scheinker disease, Kuru and fatal familial insomnia, primary lateral sclerosis, degenerative ataxias, Machado-Joseph disease / spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, spinal and spinobulbar muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, Tay-Sach's disease, multisystem degeneration (Shy-Drager syndrome), Gilles De La Tourette's disease, familial dysautonomia (Riley-Day syndrome), Kugelberg-Weiander disease, subacute sclerosing panencephalitis, Werdnig-Hoffmann disease, synucleinopathies (including multiple system atrophy), Sandhoff disease, cortical basal degeneration, spastic paraparesis, primary progressive aphasia, progressive multifocal leukoencephalopathy, striatonigral degeneration, familial spastic disease, chronic epileptic conditions associated with neurodegeneration, Binswanger's disease, and dementia (including all underlying etiologies of dementia). Examples of chronic neurodegenerative diseases include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, CAG trinucleotide repeat ataxias, spinocerebellar ataxia type 1 (SCA1), spinocerebellar ataxia type 2 (SCA2), spinocerebellar ataxia type 3 (SCA3), Friedrich's Ataxia, dentatorubral-pallidoluysian atrophy (DRPLA), frontotemporal lobar dementia (FTLD), spinal muscular atrophy with respiratory distress (SMARD), spinal cancers including astrocytomas and gliomas, adrenomyeloneuropathy (AMN), giant axonal neuropathy, hereditary spastic paraplegias (HSPs), and ALS, among others. Chronic neurodegenerative diseases include diseases that feature TDP-43 proteinopathy, which is characterized by nucleus to cytoplasmic mislocalization, deposition of ubiquitinated and hyper-phosphorylated TDP-43 into inclusion bodies, protein truncation leading to formation of toxic C-terminal TDP-43 fragments, and protein aggregation. TDP-43 proteinopathy diseases include ALS, FTLD, primary lateral sclerosis, progressive muscular atrophy, limbic-predominant age-related TDP-43 encephalopathy, chronic traumatic encephalopathy, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy (PSP), dementia Parkinsonism ALS complex of guam (G-PDC), Pick’s disease, hippocampal sclerosis, Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease. Acute neurodegeneration may be caused by ischemia (e.g., traumatic brain injury), axonal transection by demyelination or trauma (e.g., spinal cord injury or multiple sclerosis). A neurodegenerative disease may exhibit death of mainly one type of neuron or of multiple types of neurons.
[0159] As used herein, “Alzheimer’s disease” and “AD” refer to a late-onset neurodegenerative disorder presenting as cognitive decline, loss of short- and long-term memory, attention deficits, language-specific problems, disorientation, impulse control, social withdrawal, anhedonia, and other symptoms. Brain tissue of AD patients exhibits neuropathological features such as extracellular aggregates of amyloid-p protein and neurofibrillary tangles of hyperphosphorylated microtubule-associated tau proteins. Accumulation of these aggregates is associated with neuronal loss and atrophy in a number of brain regions including the frontal, temporal, and parietal lobes of the cerebral cortex as well as subcortical structures like the basal forebrain cholinergic system and the locus coeruleus within the brainstem. AD is also associated with increased neuroinflammation characterized by reactive gliosis and elevated levels of pro-inflammatory cytokines.
[0160] As used herein, “pain” refers to physical suffering or discomfort caused by illness or injury. Pain intensity experienced by patients can be ranked clinically using pain scales to assess acute, chronic andATTORNEY DOCKET NO: 51861-002W02
[0161] neuropathic pain. As used herein, “neuropathic pain” refers to pain caused by neurological diseases or disorders.
[0162] Exemplary pain scales include, but are not limited to, the Numerical Rating Score (NRS), the Neuropathic Scale (NPS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS). For example, the “Numerical Rating Score” (NRS) refers to a score within an 11 -point numerical scale of 0-10 that indicates the degree of pain experienced by a patient. For instance, a score of 0 may indicate the patient is experiencing no pain, while scores from 1-3 may indicate that the patient is experiencing mild pain. A score of from 4-6 may indicate that the patient is experiencing moderate pain, and a score of from 7-10 may indicate that the patient is experiencing severe pain. Typically, to determine a NRS score, the patient is asked to indicate the level of pain currently being experienced, as well as the pain experienced at its most intense and least intense occurrences. Methods for determining an NRS, an NPS, and a LANSS are described in detail, e.g., in McCaffery et al., Pain: Clinical Manual for Nursing Practice.
[0163] (Baltimore, 1993) or May, S et al. Diagnosis and assessment of neuropathic pain. F1000 Medicine Reports 1 (2009), the disclosures of which are incorporated herein by reference as they pertain to methods for obtaining and evaluating an NRS, an NPS, and a LANSS.
[0164] Exemplary preclinical models of neuropathic pain include, but are not limited to, the spared nerve injury, spinal nerve ligation, chronic constriction injury, streptozotocin-induced diabetic neuropathy, chemotherapy-induced peripheral neuropathy (with paclitaxel), and reserpine-driven fibromyalgia models. Further methods of treatment and pain measurements in preclinical animal neuropathic pain models are described in detail in, Jaggi etal. Animal models of neuropathic pain. Fundamental & Clinical Pharmacology 25, 1-28 (2011), the contents of which are incorporated herein by reference. Exemplary preclinical models of inflammatory pain include, but are not limited to, the administration of Complete Freund’s Adjuvant (CFA) or carrageenan in an animal subject. Exemplary pain assessments in animal models include, but are not limited to, the Randall-Selitto analgesiometer, Von Frey fiber test, formalin test, tail flick test, behavioral tests (e.g., gait analysis, burrowing behavior), cold allodynia tests (e.g., acetone test) and / or hot plate sensitivity.
[0165] As used herein, “hyperalgesia” refers to a condition characterized by increased sensitivity to pain, wherein a subject, such as a patient, experiences unusually severe pain in response to painful stimuli. Hyperalgesia may occur as a symptom resulting from diseases, disorders or injury, that cause damage to the nervous system. As used herein, “allodynia” refers to a condition characterized by pain due to a stimulus that does not normally provoke pain, such as a light touch or gentle pressure on the skin. As used herein, “cold allodynia” refers to pain resulting from low-threshold cold stimuli.
[0166] As used herein, the term “blood-brain barrier,” abbreviated as BBB, refers to the selective physiological and metabolic substance diffusion barrier between the circulatory system and the central nervous system.
[0167] As used herein, the term “blood-spinal cord barrier,” abbreviated as BSCB, refers to the selective physiological and metabolic substance diffusion barrier between blood circulation and spinal cord tissues.
[0168] As used herein, the term “blood-nerve barrier,” abbreviated as BNB, refers to a selective physiological and metabolic diffusion barrier between one or more peripheral nerves and the bloodstream. Nerve lesions may trigger alterations in the microenvironment, such as the BBB, BSCB, or BNB, that contribute to the pathogenesis of neurological diseases. In certain cases, these diseases may additionally contribute to the underlying etiology of neuropathic pain.ATTORNEY DOCKET NO: 51861-002W02
[0169] As used herein, the terms “subject” and “patient” refer to an organism, such as a human, that receives treatment for a particular disease or condition as described herein. For instance, a patient, such as a human patient suffering from neuropathic pain, may receive treatment in the form of a therapeutically effective dosage of parmodulin.
[0170] As used herein, the term “EC50” refers to the concentration of a substance (e.g., an agonist) that induces 50% of a maximal biological response after a specified exposure time, e.g., as measured in a ligand binding assay. As used herein, the term “IC50” refers to the concentration of a substance (antagonist) that reduces the efficacy of a reference agonist or the constitutive activity of a biological target by 50%, e.g., as measured in a competitive ligand binding assay. Exemplary ligand binding assays include radioligand binding assays, competitive enzyme-linked immunosorbent assays (ELISA), and fluorescence anisotropy-based assays, among others known in the art.
[0171] As used herein, the term “negative control” refers to one or more group(s), subject(s), condition(s), or sample(s) that are not exposed to the treatment or condition being tested, such as treatment with a compound of the disclosure.
[0172] As used herein, the term “vehicle” or “vehicle control” refers to a carrier solvent or solution, such as dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), or any other solvent or solution suitable for delivery of a compound of interest (e.g., a compound of the disclosure, such as a parmodulin recited herein). In some embodiments, a “vehicle” or “vehicle control” is provided to an experimental sample in the same manner as is used to deliver the compound of interest (e.g., a parmodulin of the disclosure), save for the absence of the compound.
[0173] As used herein, the term “pharmaceutical composition” refers to an active compound, formulated together with one or more pharmaceutically acceptable excipients. In some embodiments, a compound of the disclosure is present in a unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions) or tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, or pastes for application to the tongue.
[0174] The term “pharmaceutically acceptable excipient,” as used herein, refers to any inactive ingredient (for example, a vehicle capable of suspending or dissolving the active compound) having the properties of being nontoxic and non-inflammatory in a subject.
[0175] As used herein, the term “pharmaceutically acceptable salt” represents those salts of the compounds described that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit / risk ratio. Examples of pharmaceutically acceptable counterions are described in P. Heinrich Stahl. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. (John Wiley & Sons, 2008). These salts may be acid addition salts involving inorganic or organic acids. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting the free base group with a suitable acid.
[0176] As used herein, the term “therapeutically effective amount” refers to an amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, a “therapeutically effective amount”ATTORNEY DOCKET NO: 51861-002W02
[0177] depends upon the context in which it is being applied. For example, in the context of administering a compound disclosed herein (e.g., a compound of any one of Formula (l-X)), a “therapeutically effective amount” may referto an amount sufficient to alleviate pain (e.g., pain resulting from an underlying neurological disorder, among various other potential underlying causes disclosed herein).
[0178] As used herein, the term “optionally substituted” refers to a chemical moiety that may have one or more chemical substituents, as valency permits, such as C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkynyl, C1-C10 cycloalkyl, C1-C10 heterocycloalkyl, C1-C10 aryl, C1-C10 alkylaryl, C1-C10 heteroaryl, C1-C10 alkylheteroaryl, amino, ammonium, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, ureido, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, and the like. An optionally substituted chemical moiety may contain, e.g., neighboring substituents that have undergone ring closure, such as ring closure of vicinal functional substituents, thus forming, e.g., lactams, lactones, cyclic anhydrides, acetals, thioacetals, or aminals formed by ring closure, for instance, in order to generate a protecting group.
[0179] As used herein, the term “alkyl” refers to a straight- or branched-chain alkyl group having, for example, from 1 to 20 carbon atoms in the chain. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like.
[0180] The term “aliphatic” refers to a non-aromatic moiety that may be saturated (e.g., single bond) or contains one or more units of unsaturation (e.g., double and / or triple bonds). An aliphatic group may be straight chained, branched, or cyclic, contain carbon, hydrogen or, optionally, one or more heteroatoms and may be substituted or unsubstituted. In addition to aliphatic hydrocarbon groups, aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines. Such aliphatic groups may be further substituted. It is understood that aliphatic groups may include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, and substituted or unsubstituted cycloalkyl groups as described herein.
[0181] As used herein, the term “cycloalkyl” refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated and has, for example, from 3 to 12 carbon ring atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[3.1.0]hexane, and the like.
[0182] As used herein, the term “heterocycloalkyl” refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated and has, for example, from 3 to 12 ring atoms per ring structure selected from the group consisting of carbon atoms and heteroatoms selected from the group consisting of, e.g., nitrogen, oxygen, and sulfur, among others. The ring structure may contain, for example, one or more oxo groups on carbon, nitrogen, or sulfur ring members.
[0183] As used herein, the term “aryl” refers to a monocyclic or multicyclic aromatic ring system containing, for example, from 6 to 19 carbon atoms. Aryl groups include, but are not limited to, phenyl, fluorenyl, naphthyl, and the like.
[0184] As used herein, the term “heteroaryl” refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Heteroaryl groups include pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadia-zolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl,ATTORNEY DOCKET NO: 51861-002W02
[0185] isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5, 6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl, benzoquinolyl, and the like.
[0186] For simplicity, chemical moieties that are defined and referred to throughout can be univalent chemical moieties (e.g., alkyl, aryl, etc.) or multivalent moieties under the appropriate structural circumstances clear to those skilled in the art. For example, an “alkyl” moiety can be referred to a monovalent radical (e.g., -CH2-CH2- ), or in other instances, a bivalent linking moiety can be “alkyl,” in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., -CH2-CH2-), which is equivalent to the term “alkylene.” Similarly, in circumstances in which divalent moieties are required and are stated as being “alkoxy”, “alkylamino”, “aryloxy”, “alkylthio”, “aryl”, “heteroaryl”, “heterocyclic”, “alkyl” “alkenyl”, “alkynyl”, “aliphatic”, or “cycloalkyl”, those skilled in the art will understand that the terms “alkoxy”, “alkylamino”, “aryloxy”, “alkylthio”, “aryl”, “heteroaryl”, “heterocyclic”, “alkyl”, “alkenyl”, “alkynyl”, “aliphatic”, or “cycloalkyl” refer to the corresponding divalent moiety.
[0187] The term “halogen” as used herein, refers to an atom selected from fluorine, chlorine, bromine and iodine.
[0188] Parmodulins
[0189] Compositions for use with methods described herein may include one or more parmodulin compounds. In some embodiments, parmodulins disclosed herein may be a biased, allosteric ligand of PARI. In some embodiments, parmodulins disclosed herein may selectively augment PAR1 -driven p-arrestin activity by acting as a positive modulator of PAR1. In some embodiments, parmodulins may also exhibit a direct agonist effect on PAR1. In some embodiments, a parmodulin may be an ago-PAM. In some embodiments, parmodulins are not direct PAR1 agonists. In some embodiments, parmodulins increase p-arrestin recruitment and may simultaneously inhibit PAR1 -driven Gq signaling. One or more parmodulins useful according to the present disclosure are known in the art and can be found in any of the following: De Ceunynck, K. etal. PAR1 Agonists Stimulate APC-like Endothelial Cytoprotection and Confer Resistance to Thromboinflammatory Injury. PNAS 115(5), E982-E991, (2018); Flaumenhaft, R. and De Ceunynck, K. Targeting PAR1: Now What? Trends Pharmacol. Sci. 38(8), 701-716 (2017); Aisuku, O. etal. Parmodulins Inhibit Thrombus Formation Without Inducing Endothelial Injury Caused by Vorapaxar. Blood 125(12), 1976-1985 (2015); Dockendorff, C. etal. Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Med. Chem. Lett. 3(3), 232-237 (2012); Dowal, L. etal. Identification of an Antithrombotic Allosteric Modulator That Acts Through Helix 8 of PARI. Proceedings of the National Academy of Sciences 108(7), 2951-2956 (2011); Gandhi, D. M. et al. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells. Bioorg. Med. Chem. 26(9), 2514-2529 (2018); Gandhi, D. M. etal. The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability Bioorg. Med. Chem. 27(7), 3788-3796 (2019); Nazir, S. et al. Cytoprotective Activated Protein C Averts Nlrp3 Inflammasome-lnduced Ischemia-Reperfusion Injury via mTORCI Inhibition. Blood 130(24), 2664-2677 (2017); VerPlank L. etal. Chemical Genetic Analysis of Platelet Granule Secretion-Probe 3. In: Probe Reports from the NIH Molecular Libraries Program.
[0190] Bethesda (MD): National Center for Biotechnology Information (US); 2010; VerPlank L. et al. ChemicalATTORNEY DOCKET NO: 51861-002W02
[0191] Genetic Analysis of Platelet Granule Secretion-Probe 2. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010;
[0192] Flaumenhaft, R. etal. Identification of a Novel Pari inhibitor Using a Chemical Genetic Screen. Blood 116(21), 2018 (2010); WO 2018183122; WO 2008058096; WO 2012040636; US Pat. No. 9,422,262; US Pat. No. 11,130,743; or US Pat. No. 7,166,612; each of which is incorporated herein by reference in its entirety, including the compound structures disclosed therein.
[0193] Parmodulins for use with the methods described herein include compounds represented by Formula (I), Formula (II), Formula (III), or Formula (IV):
[0194]
[0195] wherein each R1and R2is independently selected from the group consisting of absent, hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl;
[0196] each X1, X2, and X3is independently selected from the group consisting of a covalent bond, -[C(R10)(R11)]V-, -S-, -O-C(R12)=C(R13)-, -C(OR15)(R14)-, -N(R16)-, and -C(O)-; wherein v is 0, 1, 2, or 3; each R10, R11, R12, R13, and R14is independently selected from the group consisting of covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R11, R12, R13, R14, R15,orR16 together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
[0197] X4is selected from the group consisting of -N(R15)-, -C(O)-, -C(OR16)-, -C(R10)-, and -C(R11)=C(R12)-;
[0198] each X5and X6is independently selected from the group consisting of a covalent bond, -NR15-, -O-, and -CR16R10-;ATTORNEY DOCKET NO: 51861-002W02
[0199] each G1and G2is independently selected from the group consisting of absent, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; and
[0200] t is 0, 1, 2, or 3,
[0201] as well as salts thereof.
[0202] In some embodiments, ring A is selected from the group consisting of:
[0203]
[0204] wherein each R100, R101, and R102is independently selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl, wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
[0205] In some embodiments, R1is selected from the group consisting of hydrogen and CH3. In some embodiments, R1is hydrogen. In some embodiments, R2is selected from the group consisting of hydrogen and CH3. In some embodiments, R2is hydrogen.ATTORNEY DOCKET NO: 51861-002W02
[0206] In some embodiments, G1is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl. In some embodiments, G1is selected from the group consisting of:
[0207]
[0208] wherein each X7and X8is independently selected from the group consisting from O, S, and NH; R100is selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
[0209] In some embodiments, G2is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl. In some embodiments, G2is selected from the group consisting of:
[0210]
[0211] wherein each R100and R101is independently selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.ATTORNEY DOCKET NO: 51861-002W02
[0212] In some embodiments, A and G2are optionally substituted aromatic groups. In some embodiments, G2is optionally substituted aliphatic or optionally substituted alkyl. In some embodiments, G2is optionally substituted aryl or optionally substituted heteroaryl.
[0213] Parmodulins for use with the methods described herein include compounds represented by Formula (V):
[0214]
[0215] wherein each m and y is independently selected from 0, 1, 2, 3, and 4;
[0216] wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein each R10and R11is independently selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; and
[0217] wherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,
[0218] as well as salts thereof.
[0219] Parmodulins for use with the methods described herein include compounds represented by Formula (VI):
[0220]
[0221] wherein each of m and y is independently selected from 0, 1, 2, 3, and 4;
[0222] wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein each R10and R11is independently selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl,ATTORNEY DOCKET NO: 51861-002W02
[0223] optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; and
[0224] wherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,
[0225] as well as salts thereof.
[0226] Parmodulins for use with the methods described herein include compounds represented by Formula (VII):
[0227]
[0228] wherein y is selected from 0, 1, 2, 3, and 4;
[0229] wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein R10is selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; and
[0230] wherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,
[0231] as well as salts thereof.
[0232] Parmodulins for use with the methods described herein include compounds represented by Formula (VIII):
[0233]
[0234] wherein G5is selected from the group consisting of S(O2)R18, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein R18is optionally substituted alkyl.ATTORNEY DOCKET NO: 51861-002W02
[0235] wherein R1is selected from the group consisting of absent, hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively, G5and R1, or R1and R11, together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
[0236] wherein each R10and R11is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
[0237] wherein X9is N or O, with the proviso that when X9is O, R1is absent; and
[0238] wherein each m and y is independently selected from the group consisting of 0, 1, 2, 3, and 4, as well as salts thereof.
[0239] Parmodulins for use with the methods described herein include compounds represented by Formula (IX):
[0240]
[0241] wherein G5is selected from the group consisting of S(O2)R18, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein R18is optionally substituted alkyl.
[0242] wherein R1is selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively, G5and R1, or R1and R11, together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
[0243] wherein each R10and R11is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; and
[0244] wherein each m and y is independently selected from the group consisting of 0, 1, 2, 3, and 4, as well as salts thereof.ATTORNEY DOCKET NO: 51861-002W02
[0245] Parmodulins for use with the methods described herein include compounds represented by Formula (X):
[0246]
[0247] wherein each R104and R105is independently optionally substituted alkyl; and, R106is a halogen, OCH3, or OR107a; wherein R107ais optionally substituted alkyl, as well as salts thereof.ATTORNEY DOCKET NO: 51861-002W02
[0248]
[0249] ATTORNEY DOCKET NO: 51861-002W02
[0250]
[0251] ATTORNEY DOCKET NO: 51861-002W02
[0252]
[0253] ATTORNEY DOCKET NO: 51861-002W02
[0254]
[0255] ATTORNEY DOCKET NO: 51861-002W02
[0256]
[0257] as well as salts thereof.ATTORNEY DOCKET NO: 51861-002W02
[0258] Parmodulins for use with the methods described herein include compounds represented by Formula (XI):
[0259]
[0260] wherein each R201and R204is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl;
[0261] each R202and R203is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR205a, NHR205a, NR205aR205b, SR205a, S(O2)R205a, C(O)OH, C(O)OR205a, C(O)NH2, C(O)NR205aR205b, C(O)NHR205a, CF3, CN, NO2, N3, OCF3, NHC(O)R205a, C(O)R205a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R205aand R205bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
[0262] as well as salts thereof.
[0263] Particular parmodulins described herein include:
[0264]
[0265] as well as salts thereof.
[0266] Parmodulins for use with the methods described herein include compounds represented by Formula (XII):
[0267]
[0268] wherein each G3, G4, R300, and R301is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR302a, NHR302a, NR302aR302b, SR302a, S(O2)R302a, C(O)OH, C(O)OR302a, C(O)NH2, C(O)NR302aR302b, C(O)NHR302a, CF3, CN, NO2, N3, OCF3, NHC(O)R302a, C(O)R302a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R302aand R302bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substitutedATTORNEY DOCKET NO: 51861-002W02
[0269] heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl,
[0270] as well as a salt thereof.
[0271] Particular parmodulins described herein include:
[0272]
[0273] 162 163
[0274] as well as salts thereof.
[0275] Where the number of any given substituent is not specified, there may be one or more substituents present. For example, “optionally substituted alkyl” may include one or more of the same or different alkyl groups.
[0276] When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms of carbonyl-containing compounds are also intended to be included.
[0277] It is to be understood that the compounds provided herein may contain chiral centers. Such chiral centers may be of either the ( / ?) or (S) configuration or may be a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure or may be stereoisomeric or diastereomeric mixtures. As such, one of skill in the art will recognize that administration of a compound in its ( / ?) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form.
[0278] Compounds described herein include, but are not limited to, those set forth above, as well as any of their isomers, such as diastereomers and enantiomers, as well as salts, esters, amides, thioesters, solvates, and polymorphs thereof, as well as racemic mixtures and pure isomers of the compounds set forth above.
[0279] In some embodiments, one or more compounds depicted herein may exist in different tautomeric forms. As will be clear from context, unless explicitly excluded, references to such compounds encompass all such tautomeric forms. In some embodiments, tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton. In certain embodiments, a tautomeric form may be a prototropic tautomer, which is an isomeric protonation state having the same empirical formula and total charge as a reference form. Examples of moieties with prototropic tautomeric forms are ketone — enol pairs, amide — imidic acid pairs, lactam — lactim pairs, amide — imidic acid pairs, enamine — imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. In some embodiments, tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. In certain embodiments, tautomeric forms result from acetal interconversion.ATTORNEY DOCKET NO: 51861-002W02
[0280] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as2H,3H,11C,13C,14C,13N,15N,150,17O,18O,32P,33P,35S,18F,36CI,123l and125l, among others. Isotopically-labeled compounds (e.g., those labeled with3H and14C) can be useful in compound or substrate tissue distribution assays. Tritiated (i.e.,3H) and carbon-14 (i.e.,14C)) isotopes can be useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e.,2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, one or more hydrogen atoms are replaced by2H, D, or3H, or one or more carbon atoms are replaced by13C- or14C-enriched carbon. Positron emitting isotopes such as150,13N,11C, and18F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Preparations of isotopically labelled compounds are known to those of skill in the art. For example, isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed for compounds of the present invention described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
[0281] Pharmaceutical Compositions
[0282] Parmodulins suitable for use with the compositions and methods described herein can be formulated into a pharmaceutical composition for administration to a patient, such as a human patient, in a biologically compatible form suitable for administration in vivo. A pharmaceutical composition containing a parmodulin, such as a compound described herein (e.g., / V-[3-(2-bromobenzamido)phenyl]-1,3-oxazole-5-carboxamide (45) or a pharmaceutically acceptable salt thereof, such as the hydrochloride salt thereof), may additionally contain a suitable diluent, carrier, or excipient. Parmodulins can be administered to a patient, for example, orally, intravenous, intraperitoneal, subcutaneously, retro-orbitally, topically, or orally, among others. Under ordinary conditions of storage and use, a pharmaceutical composition may contain a preservative, (e.g., to prevent the growth of microorganisms). Pharmaceutical compositions containing a parmodulin or a pharmaceutically acceptable salt thereof, can be prepared using methods known in the art. Procedures and ingredients for the preparation of suitable formulations are described, for example, in Beringer, P. Remington: The Science and Practice of Pharmacy (Linppincott Williams & Wilkins, 2012) and in The United States Pharmacopeia: The National Formulary (United States Pharmacopeial Convention NF 33, 2015).
[0283] Pharmaceutical compositions may include sterile aqueous solutions, dispersions, or powders, (e.g., for the extemporaneous preparation of sterile solutions or dispersions). In all cases the form may be sterilized using techniques known in the art and may be fluidized to the extent that may be easily administered to a patient in need of treatment.
[0284] A pharmaceutical composition may be administered to a patient, e.g., a human patient, alone or in combination with one or more pharmaceutically acceptable carriers, e.g., as described herein, the proportion of which may be determined by the solubility and / or chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice.ATTORNEY DOCKET NO: 51861-002W02
[0285] Routes of Administration
[0286] The compounds described herein may be administered to a patient in need thereof (e.g., a patient suffering from pain or a neurological disease) by way of various routes, including orally. Oral administration is particularly desirable, as its convenience and ease of self-administration are conducive to repeated dosing, when needed.
[0287] The compounds described herein may also be administered by way of one or more of a variety of other routes. In addition to the oral route described above, compounds of the disclosure may be administered by way of, without limitation, enteral (into the intestine), gastroenteral, epidural (into the dura matter), transdermal, by inhalation (through the nose or mouth, via spray, aerosol, or dry powder) peridural, intracerebral (into the cerebrum), intracerebroventricular (into the cerebral ventricles), epicutaneous (application onto the skin), intradermal, (into the skin itself), subcutaneous (under the skin), intravenous bolus, intravenous drip, intraarterial (into an artery), intramuscular (into a muscle), intrathecal (into the spinal canal), intraperitoneal, (infusion or injection into the peritoneum), intravesical infusion, transdermal (diffusion through the intact skin for systemic distribution), transmucosal (diffusion through a mucous membrane), sublingual, intravascular (within a vessel or vessels), intraventricular (within a ventricle), iontophoresis (by means of electric current where ions of soluble salts migrate into the tissues of the body), irrigation (to bathe or flush open wounds or body cavities), laryngeal (directly upon the larynx), nasogastric (through the nose and into the stomach), occlusive dressing technique (topical route administration that is then covered by a dressing that occludes the area), oropharyngeal (directly to the mouth and pharynx), parenteral, percutaneous, periarticular, peridural, perineural, periodontal, rectal, retrobulbar (behind the pons or behind the eyeball), intramyocardial (entering the myocardium), submucosal, or topical.
[0288] The most suitable route for administration in any given case will depend on the particular composition administered, the subject, pharmaceutical formulation methods, administration methods (e.g., administration time and administration route), the subject's age, body weight, sex, severity of the diseases being treated, the subject's diet, and the subject's excretion rate, among others. Multiple routes of administration may be used to treat a single subject, e.g., IM and IV, among others. Multiple routes of administration may be used to treat a single subject at one time, or the subject may receive treatment via one route of administration first and receive treatment via another route of administration during a second appointment, e.g., 1 week later, 2 weeks later, 1 month later, 6 months later, or 1 year later.
[0289] In vitro Models and Measurements to Assess Selective PAR1 -driven p-arrestin Activity
[0290] (i) PAR1 p-arrestin recruitment assay
[0291] A practitioner of skill in the art may utilize a PAR1 p-arrestin recruitment assay to assess whether a given compound (e.g., a compound disclosed herein) drives p-arrestin activity by acting as a positive modulator of PAR1. In some embodiments, a PAR1 p-arrestin recruitment assay measures a change in fluorometric, luminescent, colorimetric (e.g., change in absorbance), radioactive, and / or chemical signal relative to a baseline measurement e.g., the signal measured from untreated cells or cells treated with a vehicle control. In some embodiments, this change in signal results from an enzymatic reaction (e.g., catalyzed by p-galactosidase enzyme). In some embodiments, this change in signal is from a biosensor (e.g., a biological or chemical sensor that detects changes in a biological system).ATTORNEY DOCKET NO: 51861-002W02
[0292] In an exemplary PAR1 -dependent p-arrestin recruitment assay, cells (e.g., primary cells or an immortalized cell line, such as HEK293T) expressing PAR1 and a p-arrestin biosensor (e.g., the Borealis p-arrestin biosensor), may be treated with different concentrations of the compound of interest and control compounds, such as the known PAR1 agonist TFLLR-NH2. Activation of the p-arrestin-2 biosensor may be quantified by a change in signal intensity from the biosensor (e.g., a change in fluorescent intensity) upon activation. By taking measurements prior to and after agonist addition, compounds can be characterized as PAR1- p-arrestin agonists, inverse agonists, antagonists, or positive allosteric modulators, as shown in Example 1, FIG. 2.
[0293] In another exemplary PAR1 -dependent p-arrestin recruitment assay, cells (e.g., primary cells or an immortalized cell line, such as CHO-K1 epithelial cells) expressing modified versions of PAR1 and p-arrestin-2 containing complementary portions of a p-galactosidase enzyme, may be treated with different concentrations of the compound of interest and control compounds, such as the known PAR1 agonist TFLLR-NH2. Following, incubation with a ligand, a reagent cocktail including luminescent p-galactosidase substrate can be added to the cells, and the change in signal can be measured, e.g., by plate reader.
[0294] (ii) PAR2 p-arrestin recruitment assay
[0295] Fora given compound of interest, utilizing both PAR1 and PAR2 p-arrestin recruitment assays in combination provides confirmation that that p-arrestin recruitment is selectively dependent on PAR1 and not driven by the closely related receptor PAR2. A practitioner of skill in the art may utilize a PAR2-dependent p-arrestin-2 recruitment assay to assess whether a given compound (e.g., any of the parmodulins disclosed herein) drives p-arrestin activity through PAR2.
[0296] In some embodiments, a PAR2 p-arrestin recruitment assay measures a change in fluorometric, luminescent, colorimetric (e.g., change in absorbance), radioactive, and / or chemical signal relative to a baseline measurement e.g., the signal measured from untreated cells or cells treated with a vehicle control. In some embodiments, this change in signal is from an enzymatic reaction (e.g., catalyzed by p-galactosidase enzyme). In some embodiments, this change in signal is from a biosensor (e.g., a biological or chemical sensor that detects changes in a biological system).
[0297] In an exemplary PAR2-dependent p-arrestin-2 recruitment assay, cells (e.g., primary cells or an immortalized cell line, such as HEK293T) can be plated and transfected with PAR2 and the Borealis p-arrestin-2 biosensor, then treated with different concentrations of the compound of interest and control compounds, e.g., the known PAR2 agonist 2-furoyl-LIGRLO. In some embodiments, compounds with EC50 < 10 pM (e.g., about 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 210 nM, 220 nM, 230 nM, 240 nM, 250 nM, 260, nM, 270 nM, 280 nM, 290 nM, 300 nM, 310 nM, 320 nM, 330 nM, 340 nM, 350 nM, 360 nM, 370 nM, 380 nM, 390 nM, 400 nM, 410 nM, 420 nM, 430 nM, 440 nM, 450 nM, 460, nM, 470 nM, 480 nM, 490 nM, 500 nM, 510 nM, 520 nM, 530 nM, 540 nM, 550 nM, 560 nM, 570 nM, 580 nM, 590 nM, 600 nM, 610 nM, 620 nM, 630 nM, 640 nM, 650 nM, 660 nM, 670 nM, 680 nM, 690 nM, 700 nM, 710 nM, 720 nM, 730 nM, 740 nM, 750 nM, 760 nM, 770 nM, 780 nM, 790 nM, 800 nM, 810 nM, 820 nM, 830 nM, 840 nM, 850 nM, 860 nM, 870 nM, 880 nM, 890 nM, 900 nM, 910 nM, 920 nM, 930 nM, 940 nM, 950 nM, 960 nM, 970 nM, 980 nM, 990 nM, 1 pM, 1.1 pM, 1.2 pM, 1.3 pM, 1.4 pM, 1.5 pM, 1.6 pM, 1.7 pM, 1.8 pM, 1.9 pM, 2 pM, 2.1 pM, 2.2 pM, 2.3 pM, 2.4 pM, 2.5 pM, 2.6 pM, 2.7 pM, 2.8 pM, 2.9 pM, 3 pM, 3.1 pM, 3.2 pM, 3.3 pM, 3.4 pM, 3.5 pM, 3.6 pM, 3.7 pM, 3.8 pM, 3.9 pM, 4 pM, 4.1 pM, 4.2 pM, 4.3 pM, 4.4 pM, 4.5 pM, 4.6 pM, 4.7 pM, 4.8 pM, 4.9 pM, 5 pM, 5.1 pM, 5.2ATTORNEY DOCKET NO: 51861-002W02
[0298] pM, 5.3 pM, 5.4 pM, 5.5 pM, 5.6 pM, 5.7 pM, 5.8 pM, 5.9 pM, 6 pM, 6.1 pM, 6.2 pM, 6.3 pM, 6.4 pM, 6.5 pM, 6.6 pM, 6.7 pM, 6.8 pM, 6.9 pM, 7 pM, 7.1 pM, 7.2 pM, 7.3 pM, 7.4 pM, 7.5 pM, 7.6 pM, 7.7 pM, 7.8 pM, 7.9 pM, 8 pM, 8.1 pM, 8.2 pM, 8.3 pM, 8.4 pM, 8.5 pM, 8.6 pM, 8.7 pM, 8.8 pM, 8.9 pM, 9 pM, 9.1 pM, 9.2 pM, 9.3 pM, 9.4 pM, 9.5 pM, 9.6 pM, 9.7 pM, 9.8 pM, 9.9 pM, or 10 pM) in the PAR1-driven p-arrestin activity assay and an EC50 > 100 pM (e.g., about 100 pM, 110 pM, 120 pM, 130 pM, 140 pM, 150 pM, 160 pM, 170 pM, 180 pM, 190 pM, 200 pM, 210 pM, 220 pM, 230 pM, 240 pM, 250 pM, 260, pM, 270 pM, 280 pM, 290 pM, 300 pM, 310 pM, 320 pM, 330 pM, 340 pM, 350 pM, 360 pM, 370 pM, 380 pM, 390 pM, 400 pM, 410 pM, 420 pM, 430 pM, 440 pM, 450 pM, 460, pM, 470 pM, 480 pM, 490 pM, 500 pM, 510 pM, 520 pM, 530 pM, 540 pM, 550 pM, 560 pM, 570 pM, 580 pM, 590 pM, 600 pM, 610 pM, 620 pM, 630 pM, 640 pM, 650 pM, 660 pM, 670 pM, 680 pM, 690 pM, 700 pM, 710 pM, 720 pM, 730 pM, 740 pM, 750 pM, 760 pM, 770 pM, 780 pM, 790 pM, 800 pM, 810 pM, 820 pM, 830 pM, 840 pM, 850 pM, 860 pM, 870 pM, 880 pM, 890 pM, or 900 pM) in the PAR2-driven p-arrestin activity assay will be considered PAR1 -selective activators of p-arrestin recruitment.
[0299] In another exemplary PAR2-dependent p-arrestin recruitment assay, cells (e.g., primary cells or an immortalized cell line, such as CHO-K1 epithelial cells) expressing modified versions of PAR2 and p-arrestin-2 containing complementary portions of a p-galactosidase enzyme, may be treated with different concentrations of the compound of interest and control compounds, such as the known PAR2 agonist SLIGRL-NH2. Following, incubation with a ligand, a reagent cocktail including luminescent p-galactosidase substrate can be added to the cells, and the change in signal can be measured by plate reader.
[0300] (Hi) PAR-driven intracellular calcium mobilization (ICa2+)
[0301] Further validation that a compound of interest selectively acts through PAR1 and not PAR2 can be determined by assessing the compound’s ability to inhibit PAR-driven intracellular calcium mobilization. Gq signaling can be measured from its downstream effects in these PAR1 -expressing cells, such as increases in calcium mobilization or platelet P-selectin release. For example, in some embodiments, compounds at a concentration of 10 pM that inhibit PAR1 -driven calcium mobilization (using the PAR1 agonist SFLLRN-NH2 at 5 pM) by at least 50% may be considered as meeting the criteria for inhibitors (antagonists) of PAR1 -driven Gq activity.
[0302] In an exemplary intracellular calcium mobilization assay, adherent cells (e.g., a suitable endothelial or epithelial cell, such as EA.hy926) expressing PAR1 and PAR2 are treated with compounds of interest to assess the compound’s ability to inhibit calcium mobilization induced by a PAR1 agonist (such as SFLLRN-NH2), or a PAR2 agonist (such as 2-furoyl-LIGRLO). Intracellular calcium may be measured using a calcium indicator, e.g., a cell-permeable, fluorescent calcium indicator, such as Fluo4 / AM. 8-point concentration-response curves are typically determined (n=2 or more).
[0303] (iv) In vitro Neuroprotection Assays
[0304] In vitro neuroprotection assays may utilize a variety of chemical agents (e.g., thrombin or a chemotoxic agent) and / or conditions (e.g., physical stress or hyperglycemic conditions) to simulate a range of neurological conditions.
[0305] In some embodiments, compounds disclosed herein (e.g., parmodulins) may increase neuronal cell viability and / or decrease neurite fragmentation in the presence of an agent known to initiateATTORNEY DOCKET NO: 51861-002W02
[0306] neuroinflammation, such as thrombin. In some embodiments, compounds disclosed herein (e.g., parmodulins) may also increase neuronal cell viability, decrease neurite fragmentation, and / or decrease injury markers under conditions of excitotoxicity (elevated concentrations of glutamate or N-methyl-D-aspartate (NMDA)), physical injury, chemical injury, and / or cytokine or neurotoxic peptide injury. In some embodiments, compounds disclosed herein (e.g., parmodulins) may also decrease the activation of microglia and astrocytes under inflammatory conditions (e.g., under conditions of elevated concentrations of LPS orTNF-a), with or without the presence of an exogenous PAR1 activator, such as plasmin, thrombin, or a matrix metalloprotease. This is expected to indirectly minimize damage to neurons.
[0307] In some embodiments, the efficacy of the disclosed compound(s) in these injury models is expected to be higher in the presence of an inflammatory PAR1 activator, such as thrombin. This is highly relevant to conditions of neuropathic pain, neuronal injury, and / or neurodegeneration, because inflammatory, PAR1 -activating agents such as thrombin are frequently present in elevated concentrations under these circumstances, and elevated expression of PAR1 may also occur within injured tissues in the peripheral or central nervous system.
[0308] In some embodiments, the in vitro neuroprotection assays utilize immortalized cell lines, primary cells, or pluripotent stem cells (e.g., induced pluripotent stem cells or embryonic pluripotent stem cells). In some embodiments, the cells originate from a non-human animal (e.g., a mouse, rat, or non-human primate). In some embodiments, the cells originate from a human.
[0309] Exemplary in vitro neuroprotection assays are described in Examples 9-17.
[0310] Models and Measurements of Pain and Neurological Dysfunction
[0311] Neuropathic Pain Models
[0312] Utilizing the methods disclosed herein, a practitioner of skill in the art can treat an animal subject to evaluate the ability of a compound to alleviate neuropathic pain. Several non-limiting exemplary animal models of neuropathic pain, which simulate clinical pain conditions with diverse etiology, are disclosed below. Further methods of treatment and pain measurements in preclinical animal neuropathic pain models are described in detail in, Jaggi et al. Animal models of neuropathic pain. Fundamental & Clinical Pharmacology 25, 1-28 (2011), the contents of which are incorporated herein by reference.
[0313] (I) Streptozotocin (STZ)-induced diabetic neuropathy model
[0314] The STZ-induced rat model reproduces metabolic lesional mechanisms of Type 1 Diabetes Mellitus and is a commonly used model of diabetic neuropathy. STZ, an alkylating and antimicrobial agent, selectively destroys pancreatic beta cells through DNA alkylation. Typically, diabetes can be induced by a single intraperitoneal or intravenous injection of STZ at a relatively high dose. This leads to prolonged hyperglycemia, hypoinsulinemia, and abnormal glucose metabolism, which may cause the degeneration of neurons. Decreases in neurotrophic factors occur in STZ-induced diabetic animals, such as mice or rats, that parallel those in human patients with diabetic neuropathy, and this, in turn, exacerbates the degeneration of neurons. Slowing of nerve conduction velocity (NCV), a conventional electrophysiological parameter that reflects the severity of nerve dysfunction, also occurs in STZ-induced diabetic animals as in patients with diabetic neuropathy. In addition, STZ-induced diabetic rats show neuropathic pain, characterized by mechanical and thermal allodynia, one of the symptoms of diabetic neuropathy. Gabapentin, pregabalin, amitriptyline, mexiletine, and morphine, but not diclofenac, inhibitATTORNEY DOCKET NO: 51861-002W02
[0315] allodynia in a rodent model of STZ-induced diabetic neuropathy, suggesting that the STZ model is suitable for evaluating the clinical potential of compounds for treating painful diabetic neuropathy.
[0316] (ii) Genetic models of Type 2 diabetes
[0317] Models of Type 2 diabetes (T2D) have been developed using rodents with mutations involving the hormone leptin (e.g., ob / ob mice) or its receptor (e.g., db / db mice). These mutations result in hyperphagia and consequent obesity, hyperglycemia, and reduced insulin sensitivity. These models can optionally be combined with high fat diets to give rodents with varying levels of neuropathy, including hyperalgesia and allodynia. These models have been reviewed, for example, by O’Brien, RD. etal. in Mouse Models of Diabetic Neuropathy, ILAR J 54, 259-272 (2014), the contents of which are incorporated herein by reference.
[0318] (Hi) Chemotherapy-induced peripheral neuropathy model
[0319] Chemotherapy-induced peripheral neuropathy (CIPN) may be induced with chemotherapeutic agents, such as paclitaxel, in animal models, such as rats or mice. These animals model the pain human patients may experience following neurological damage upon administration of chemotherapy, which involves sensory predominant pain that may cause long-term morbidity in survivors. Symptoms of sensory disturbance reported by human patients include, but are not limited to, numbness or tingling, and, infrequently, pain and cold allodynia. Animal models of CIPN may be induced with a range of chemotherapeutic agents, including - without limitation - vincristine, paclitaxel, cisplatin, oxaliplatin, and bortezomib. As a non-limiting example, mice can be dosed intraperitoneally or intravenously with paclitaxel to induce CIPN. Exemplary methods of treatment involve repeat intraperitoneal or intravenous injections of paclitaxel to simulate chemotherapeutic treatment used in human subjects. Doses of paclitaxel typically fall within the range of 3-30 mg / kg when delivered intravenously or intraperitoneally. Experimental methods for generation and validation of CIPN animal models are described, e.g., in Lv, X., etal. Animal models of chemotherapy-induced peripheral neuropathy for hematological malignancies: A review. Ibrain 9, 72-89 (2022), the contents of which are incorporated herein by reference.
[0320] (iv) Reserpine-driven fibromyalgia model
[0321] Fibromyalgia is a prevalent and burdensome disorder characterized by chronic, widespread pain. The complex physiopathology of fibromyalgia can be modeled in a preclinical animal model as described in detail, e.g., in Nakagura et al. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain 146, 26-33 (2009), the contents of which are incorporated herein by reference. Repeated administration of reserpine (e.g., 1 mg / kg subcutaneously once daily, for three consecutive days) may cause a significant decrease in the muscle pressure threshold and tactile allodynia, which may be sustained for 1 week or more in both male and female rats. An exemplary protocol may involve administering reserpine subcutaneously.
[0322] (v) Chronic Constriction Injury
[0323] Chronic neuropathic pain, resulting from damage to the central or peripheral nervous system, is a prevalent and debilitating condition. Symptoms of chronic neuropathic pain include spontaneous pain, dysaesthesia, paraesthesia, allodynia, and hyperalgesia. Several animal models mimicking peripheralATTORNEY DOCKET NO: 51861-002W02
[0324] nerve injury have been developed - one of the most widely used is unilateral sciatic nerve chronic constriction injury (CCI). CCI is performed under anesthesia. In some embodiments, an approximately 3-cm long blunt dissection is made into the skin overlying the area between the gluteus and biceps femoris muscles, and the common sciatic nerve of the hind paw is exposed at the mid-thigh level. Approximately 7 mm of the nerve is freed, proximal to the sciatic trifurcation, and four or three loose ligatures (about 1 mm spacing) of 4-0 chromic guts (or 4-0 silk) are placed around the sciatic nerve until a brief twitch is observed. The wound is closed with sutures in the muscle and staples in the skin. The animal is then allowed to recover from surgery for 24 hrs before pain hypersensitivity testing begins.
[0325] (vi) Spinal Nerve Ligation Model
[0326] SNL is a known model of the peripheral nerve injury that produces incomplete denervation of the sciatic nerve sensory territory through selective damage of a subset of spinal nerves forming the sciatic nerve. An exemplary protocol in rats involves anesthetizing and placing rats in the prone position to shave the lower back. Thereafter, a 2-cm long incision may be made at the level of the posterior iliac crest to access the left lumbar spinal nerves. L5 and L6 spinal nerves may be identified and carefully dissected free from the adjacent L4 spinal nerve, and then, tightly ligated distal to the dorsal root ganglia (DRG) using 6-0 silk suture. Anticipated operation results include long-lasting behavioral alterations such as mechanical allodynia, heat hyperalgesia, cold allodynia, and ongoing pain.
[0327] (vii) Spared Nerve Injury (SNI) model
[0328] The spared nerve injury model involves a lesion of two of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) leaving the remaining sural nerve intact. The spared nerve injury model results in early (<24 h), prolonged (>6 months), robust (all animals are responders) behavioral modifications. The mechanical (von Frey and pinprick) sensitivity and thermal (hot and cold) responsiveness is increased in the ipsilateral sural and to a lesser extent saphenous territories, without any change in heat thermal thresholds. Methodological details of the spared nerve injury model are described in detail in, Decosterd etal. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87, 149-158 (2000), the disclosure of which is incorporated herein by reference.
[0329] Acute Inflammatory Pain Models
[0330] Utilizing the compounds disclosed herein, a practitioner of skill in the art can treat an animal subject, so as to reduce or alleviate inflammatory pain. Exemplary preclinical models of inflammatory pain may involve the administration of Complete Freund’s Adjuvant (CFA) or Carrageenan in an animal subject, such as a rat or mouse. Pain, as well as these pathophysiological characteristics can be measured as described in detail, e.g., in Noh etal. Effects of difference doses of complete Freund’s adjuvant on nociceptive behavior and inflammatory parameters in polyarthritic rat model mimicking rheumatoid arthritis. PLOS ONE 16, e0260423 (2021), the contents of which are incorporated herein by reference. An exemplary protocol for a CFA rat model involves placing the rat in a temporary restraint with inhalational anesthesia until the rat is unconscious. For example, typically a concentration of 5% isoflurane (v / v) would be sufficient to induce anesthesia. Once animals have lost their righting reflex, they would remain anesthetized for ~15-20 seconds, which is adequate time to clean and inject the paw. The plantar surface on the footpad would be thoroughly cleaned with betadine and 70% ethanol. Then, theATTORNEY DOCKET NO: 51861-002W02
[0331] needle may be inserted, bevel up, into the metatarsal region of the hindpaw (just proximal to the distal calluses). Additional details and experimental considerations regarding the administration of CFA are described in detail, e.g., in Fehrenbacher etal. Models of Inflammation: Carrageenan- or Complete Freund’s Adjuvant-Induced Edema and Hypersensitivity in the Rat. Current protocols in pharmacology. 5, Unit5.4 (2012), the contents of which are incorporated herein by reference.
[0332] Neurological Disease Models
[0333] Utilizing the compounds disclosed herein, a practitioner of skill in the art can treat an animal subject, so as to treat a neurological disease (e.g., a neurodegenerative disease, such as Alzheimer's disease (AD)). In some embodiments, the neurological disease is selected from traumatic brain injury (TBI), diabetic neuropathy, amyotrophic lateral sclerosis (ALS), chemotherapy-induced neuropathy, AD, and a neurological condition resulting from surgery or physical injury. In some embodiments, the neurological disease may cause neuropathic pain. In some embodiments, the neurological disease may be neuropathic pain, e.g., due to diabetes or chemotherapy.
[0334] Exemplary preclinical models of neurological diseases include genetically engineered non-human animals, e.g., animals that have been engineered to have one or more disease-causing mutations, e.g., which have been introduced by knock-in (KI) or knock-out (KO) of genes. In some embodiments, the genetic mutations in the preclinical model directly correspond to one or more disease-causing mutations occurring in humans. Other exemplary models of neurological diseases may be created through selective surgery (e.g., nerve injury) or treatment (e.g., chemical, lifestyle, and / or pharmacological treatment). For example, a non-human animal, such as a mouse or rat, may be treated with chemotherapy agents to produce a chemotherapy-induced neuropathy preclinical model, e.g., as described herein or known in the art.
[0335] In some embodiments, the neurodegenerative disease is AD. Exemplary preclinical models of AD are well known in the art, e.g., in Zhong et. Al., Updates on mouse models of Alzheimer’s disease.
[0336] Molecular Neurodegeneration. 19, 23, (2024) and in Jankowsky et al. Practical considerations for choosing a mouse model of Alzheimer’s disease., Molecular Neurodegeneration, 12, 89 (2017), the contents of which are incorporated herein by reference. In some embodiments, the neurodegenerative disease is Parkinson’s disease. Exemplary preclinical models of Parkinson’s are well known in the art, e.g., in Dovonou et al. Animal models of Parkinson’s disease: bridging the gap between disease hallmarks and research questions., Translational Neurodegeneration, 12, 36 (2023), the contents of which are incorporated herein by reference. In some embodiments, the neurodegenerative disease is multiple sclerosis disease. Exemplary preclinical models of multiple sclerosis are well known in the art, e.g., in Dedoni et al. An overall view of the most common experimental models for multiple sclerosis. Neurobiology of disease., 184 (2023), the contents of which are incorporated herein by reference. In some embodiments, the neurodegenerative disease is ALS disease. Exemplary preclinical models of ALS are well known in the art, e.g., in Zhu et al., Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges., Translational Neurodegeneration. 12, 46 (2023), the contents of which are incorporated herein by reference.ATTORNEY DOCKET NO: 51861-002W02
[0337] Preclinical Pain and Nervous System Assessments
[0338] Effective alleviation of pain in animal models upon administration of the compounds of the disclosure may be measured through a wide range of pain assessments, including - but not limited to -the Randall-Selitto analgesiometer, Von Frey fiber test, behavioral tests (e.g., gait analysis, burrowing behavior), cold allodynia (e.g., acetone test) and / or hot plate sensitivity. In addition, the ability of compounds of the disclosure to improve neurological function may be evaluated, for example, by assessing the effects of the compounds on barrier integrity (e.g., integrity of the BBB, BSCB, and / or BNB) in a subject, as is described below.
[0339] (I) Hyperalgesia and Pain induced by Mechanical Stimuli
[0340] The Randall-Selitto test, also known as the paw pressure test, may be used to measure the response threshold to mechanical pressure stimulation in rodents. In this test, increasing mechanical pressure is applied to the surface of the paw until withdrawal or vocalization occurs. Alternatively, punctate mechanical allodynia and hyperalgesia can be evoked with a pinprick or monofilament, and in practice can be assessed in animal models by the application of von Frey filaments of varying forces (e.g., forces ranging from 0.08-2940 mN). Static hyperalgesia can be superficial or deep and is assessed by the application of pressure to the skin or underlying tissue by a finger or using a pressure algometer as described in Jensen, T. S. & Finnerup, N. B. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. The Lancet. Neurology 3, 924-35 (2014), the contents of which are incorporated herein by reference.
[0341] The formalin test permits monitoring pain-related responses (i.e., itch) caused by a subcutaneous injection of an inflammatory agent, such as a 2.5% formalin solution, in the hind paw. After the injection, two distinct time periods or phases of licking / biting behavior occur, which are separated by a quiescent period. Importantly, these phases differ in duration and underlying mechanisms. Furthermore, the formalin test allows the study of two different kinds of pain typologies: i) acute peripheral pain mediated by the direct activation of nociceptors through TRPA1 channels, and ii) inflammatory and central nociceptive sensitization. Indeed, the existence of these two phases lead to the possibility of studying different analgesic drugs, including NSAIDs and other mild analgesics, and, therefore, may allow deciphering the drug mechanism of action. Methodological details of the formalin test are described e.g., in Lopez-Cano etal. Formalin Murine Model of Pain. BIO-PROTOCOL 7, (2017), the contents of which are incorporated herein by reference.
[0342] (II) Pain induced by Thermal Stimuli
[0343] The Hargreaves test, or related hot-plate assessment, are designed to assess thermal pain sensation in rodents. For the Hargreaves test, a thermal stimulus, generated by a focused light source, is applied indirectly to the plantar surface of the hind paw of an animal. The response to this stimulus consists of withdrawal of the stimulated paw. The hot plate test is a rapid, inexpensive, reliable, and reproducible assessment of acute pain. An exemplary protocol involves placement of the animal subject on a transparent glass surface in which their movement is limited but the animal is not restrained. After the animal acclimates, the infrared (IR) source placed under the glass floor is positioned by the operator directly beneath the hind paw. Atrial is started by activating the IR source. When the animal feels pain and withdraws its paw, the IR source switches off and the reaction time counter stops. The withdrawalATTORNEY DOCKET NO: 51861-002W02
[0344] latency to the nearest 0.1s is automatically determined and recorded. If there is no response up to by 35 seconds, the test is terminated. Exemplary temperatures ranges used are 45° C to 52° C (i.e., about 45° C, 46° C, 47° C, 48° C, 49° C, 50° C, 51 ° C, or 52° C).
[0345] The tail flick test involves application of a heat stimulus to the tail of mice and rats, and the time taken for the tail to “flick” or twitch is recorded. The heat stimulus applied may be radiant heat, where a focused beam of light is applied to the tail, or hot water, where the distal end of the tail may be immersed into a water bath set at a constant temperature between 46° C and 52° C (i.e. about 46° C, 47° C, 48° C, 49° C, 50° C, 51° C, or 52° C), with the latter requiring no specialized equipment. Both versions of the test require the animal to be loosely restrained.
[0346] (Hi) Cold Allodynia
[0347] The acetone evaporation test, or related tests such as the cold plantar assay or dry ice test, are designed to generate reproducible murine behavioral responses to cold stimuli at room temperature. The acetone evaporation test measures aversive behaviors triggered by the evaporative cooling of a drop of acetone placed on the plantar surface of the hind paw. An exemplary protocol involves performing the acetone evaporation test on rats acclimated to individual chambers placed on a wire mesh floor. An acetone bubble is applied to the plantar surface of the hind paw, and these animals are monitored for a response from 0-30 seconds following acetone application. To determine sensitivity to cold, the acetone is applied 5 times (5-minute intertrial interval) to each hind paw. The outcome measured is the total number of hind paw withdrawals per application.
[0348] (iv) Behavioral assessments
[0349] Exemplary behavioral assessments of pain responses include, but are not limited to, gait and burrowing behavior analysis. Gait parameters that may be analyzed include, but are not limited to, step sequences, walking speed and duration of step placement. In addition, weight-bearing tests are commonly used to measure spontaneous pain in animals. Weight bearing tests measure the distribution of weight across the hind paws where the pressure is measured using independent pressure sensors. Unequal distribution between the ipsilateral and contralateral paws is recorded and used as an indication of the pain.
[0350] Adynamic weight-bearing (DWB) test may assess weight distribution across all four paws in freely moving animals. By calculating the weight ratio and paw surface area, the extent of pain-related changes in posture and movement may be measured.
[0351] In addition, burrowing behavior may be altered in rodent models of chronic inflammatory pain and peripheral neuropathic pain. In general, burrowing behavior is known to be altered by factors such as anxiety and distress and can be used as a behavioral endpoint for pain. An exemplary protocol for measurement of burrowing behavior and general experimental considerations are described e.g., in Muralidharan, A. etal. Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. Frontiers in Behavioral Neuroscience 10, (2016), the contents of which are incorporated herein by reference.ATTORNEY DOCKET NO: 51861-002W02
[0352] (v) Barrier permeability
[0353] Nerve lesions may trigger alterations in the microenvironment, such as the BBB, BSCB, or BNB, that contribute to neurological diseases pathogenesis. In certain cases, these diseases may be the underlying etiology of neuropathic pain. Accordingly, and without being limited by mechanism, compounds of the disclosure may ameliorate neurological dysfunction and alleviate the pain resulting therefrom by improving BBB, BSCB, and / or BNB integrity. Evaluation of BSBC permeability, for example, can be measured through staining with a dye, such as Evans’ Blue, fluorescein, IgG immunolabeling, and / or immune cell counting. Detailed methods to evaluate BSCB permeability are described e.g., in Echeverry, etal. Peripheral Nerve Injury Alters Blood-Spinal Cord Barrier Functional and Molecular Integrity through a Selective Inflammatory Pathway. Journal of Neuroscience 31, 10819-10828 (2011), the contents of which are incorporated herein by reference.
[0354] Methods of Treatment
[0355] As is described herein, the compounds of the disclosure can be administered to a patient or subject in need of treatment for pain and / or suffering from a neurological disorder. Without being limited by mechanism, PAR1 plays an important role in both coagulation and inflammation and is one of a small family of G protein-coupled receptors (GPCRs) that "self-activate" by cleavage of their / V-termini by various proteases. Cleavage of PAR1 by thrombin or other proteases, activates signaling which may lead to inflammatory effects and apoptosis. This may be associated with blood-brain barrier (BBB), blood-spinal cord barrier (BSCB) and / or blood-nerve barrier (BNB) impairment, among other phenotypes. Nerve lesions may trigger alterations in the microenvironment, such as the BBB, BSCB, or BNB, that contribute to neurological diseases pathogenesis. In certain cases, these diseases may be the underlying etiology of neuropathic pain.
[0356] However, alternative cleavage of PAR1, activation by certain agonist ligands, or positive allosteric modulation, can increase PAR1-p-arrestin signaling and gives a cytoprotective signal, which in a neurological context may provide an analgesic and / or neuroprotective effect. As described herein, the compounds of the disclosure may increase p-arrestin signaling through PARI.
[0357] The compounds of the disclosure can be administered to a patient or subject suffering from pain in order to decrease their sensitivity to pain, for example, as assessed by a pain scale. Pain intensity experienced by patients can be ranked clinically using pain scales to assess acute, chronic and neuropathic pain. Pain scales include, but are not limited to, the Numerical Rating Score (NRS), the Neuropathic Scale (NPS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS). For example, the “Numerical Rating Score” (NRS) refers to a score within an 11 -point numerical scale of 0-10 that indicates the degree of pain experienced by a patient. For instance, a score of 0 may indicate the patient is experiencing no pain, while scores from 1-3 may indicate that the patient is experiencing mild pain. A score of from 4-6 may indicate that the patient is experiencing moderate pain, and a score of from 7-10 may indicate that the patient is experiencing severe pain. Typically, to determine a NRS score, the patient is asked to indicate the level of pain currently being experienced, as well as the pain experienced at its most intense and least intense occurrences. Methods for determining an NRS, an NPS, and a LANSS are described in detail, e.g., in McCaffery et al., Pain: Clinical Manual for Nursing Practice.
[0358] (Baltimore, 1993) or May, S et al. Diagnosis and assessment of neuropathic pain. F1000 MedicineATTORNEY DOCKET NO: 51861-002W02
[0359] Reports 1 (2009), the disclosures of which are incorporated herein by reference as they pertain to methods for obtaining and evaluating an NRS, an NPS, and a LANSS.
[0360] Pain may be neuropathic and is typically measured in human patients with neuropathic pain scales, including - but not limited to - the Neuropathic Scale (NPS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
[0361] The compounds of the disclosure can be administered to a test subject (e.g., a non-human animal subject) suffering from pain to decrease their sensitivity to pain, for example, as assessed by a pain test (e.g., Hargreave’s test). Preclinical animal models of pain may be used to assess the effectiveness of pain treatment by compounds of the disclosure. Exemplary preclinical neuropathic pain models include, but are not limited to, the spared nerve injury, chronic constriction injury, streptozotocin-induced diabetic neuropathy, chemotherapy-induced peripheral neuropathy, and reserpine-driven fibromyalgia models. For example, the spared nerve injury model is an animal model of persistent peripheral neuropathic pain in which two of the three terminal branches of the sciatic nerve are damaged (tibial and common peroneal nerves) but the sural nerve is left intact, facilitating measurement of early (<24 hours), prolonged (>6 months), and robust (all animal exhibit response) behavioral modifications. Methodological details of the spared nerve injury model are described in detail in, Decosterd etal.
[0362] Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87, 149-158 (2000.), the disclosures of which are incorporated herein by reference. Methods of treatment and pain measurements in preclinical animal neuropathic pain models are described in detail in, Jaggi etal. Animal models of neuropathic pain. Fundamental & Clinical Pharmacology 25, 1-28 (2011), the disclosure of which is incorporated herein by reference as it pertains to experimental methods for using and evaluating a preclinical animal model of neuropathic pain.
[0363] Neuropathic pain may be caused, without limitation, by traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS, " Lou Gehrig's disease"), Parkinson's disease (PD), Huntington's disease (HD), Peri ventricular leukomalacia (PVL), Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, multi-infarct dementia, Pick's disease, primary lateral sclerosis, degenerative ataxias, spinal and spinobulbar muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, multisystem degeneration (Shy-Drager syndrome), familial dysautonomia (Riley-Day syndrome), subacute sclerosing panencephalitis, Sandhoff disease, cortical basal degeneration, primary progressive aphasia, familial spastic disease, Binswanger's disease, dementia (including all underlying etiologies of dementia), fibromyalgia (FM), post-herpetic neuralgia (PHN), trigeminal neuralgia (TGN), anesthesia dolorosa (AD), central pain due to multiple sclerosis (MS), focal peripheral nerve injury, or a neurological condition resulting from surgery or physical injury.
[0364] Additionally, or alternatively, the compounds of the disclosure can be used to treat a neurological disease or disorder, such as a neurodegenerative disorder. The compounds of the disclosure may be used to treat a secondary injury that results from a patient’s physiological response to an initial, also known as primary, trauma to the nervous system. Secondary injury can continue to occur for hours or weeks following the primary injury. Primary injury may be caused by trauma, including but not limited to, from traumatic brain injury (TBI), spinal cord injury, surgery or physical injury, or chemotherapy, among others. More generally, the compounds of the disclosure may be used to provide a neuroprotective impactATTORNEY DOCKET NO: 51861-002W02
[0365] on patients, which refers to interventions that prevent or limit neurological disease progression or damage from secondary injuries. Without being limited by mechanism, neuroprotective agents may function by counteracting the detrimental physiological and molecular events that result in irreversible neurological damage. Clinical results demonstrating neuroprotection include, but are not limited to, mitigating further symptom progression or alleviation of symptoms associated with neurological disorder or neurological disease. Exemplary neuroprotective benefits include, without limitation, (i) prolonging the period that patients retain functional independence in activities of daily living, (ii) reduction in neuronal damage biomarkers (e.g., matrix metalloproteinases), (iii) reduction in rate of severe adverse events (SAEs), (iv) reduction in all-cause mortality, and (v) improved cognitive or neurological function. For acute neurological injury that causes ischemia, for example resulting from ischemic stroke or TBI, additional neuroprotective benefits include (i) mitigation of growth or reduction in volume of ischemic lesion and / or infarct, or (ii) lower subsequent hemorrhage rate. Exemplary methods used to measure functional independence in activities of daily living include the Barthel Index (Bl), the modified Rankin Scale (mRS), and the Functional Independence Measure (FIM) are described in detail, e.g., in Duncan etal., Outcome Measures in Acute Stroke Trials. Stroke 31, 1429-1438 (2000), the disclosure of which is incorporated herein by reference.
[0366] Diseases that can be treated by the administration of the compounds of the disclosure to a patient include, without limitation, traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Peri ventricular leukomalacia (PVL), Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, multiinfarct dementia, Pick's disease, primary lateral sclerosis, degenerative ataxias, spinal and spinobulbar muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, multisystem degeneration (Shy-Drager syndrome), familial dysautonomia (Riley-Day syndrome), subacute sclerosing panencephalitis, Sandhoff disease, cortical basal degeneration, primary progressive aphasia, familial spastic disease, Binswanger's disease, dementia (including all underlying etiologies of dementia), or a neurological condition resulting from surgery or physical injury.
[0367] Synthesis
[0368] The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not to limit the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and / or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.
[0369] Substituent protecting groups
[0370] The synthesis of parmodulins that bind protease-activated receptor 1 (PAR1) and upregulate p-arrestin activity described herein may involve the selective protection and deprotection of alcohols, amines, ketones, sulfhydryls or carboxyl functional groups of a precursor. For example, commonly used protecting groups for amines include carbamates, such as te / Y-butyl, benzyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 9-fluorenylmethyl, allyl, and m-nitrophenyl. Other commonly used protecting groups forATTORNEY DOCKET NO: 51861-002W02
[0371] amines include amides, such as formamides, acetamides, trifluoroacetamides, sulfonamides, trifluoromethanesulfonyl amides, trimethylsilylethanesulfonamides, and tert-butylsulfonyl amides.
[0372] Examples of commonly used protecting groups for carboxyls include esters, such as methyl, ethyl, tertbutyl, 9-fluorenylmethyl, 2-(trimethylsilyl)ethoxy methyl, benzyl, diphenylmethyl, O-nitrobenzyl, orthoesters, and halo-esters. Examples of commonly used protecting groups for alcohols include ethers, such as methyl, methoxymethyl, methoxyethoxymethyl, methylthiomethyl, benzyloxymethyl, tetrahydropyranyl, ethoxyethyl, benzyl, 2-napthylmethyl, O-nitrobenzyl, P-nitrobenzyl, P-methoxybenzyl, 9-phenylxanthyl, trityl (including methoxy-trityls), and silyl ethers. Examples of commonly used protecting groups for sulfhydryls include many of the same protecting groups used for hydroxyls. In addition, sulfhydryls can be protected in a reduced form (e.g., as disulfides) or an oxidized form (e.g., as sulfonic acids, sulfonic esters, or sulfonic amides). Protecting groups can be chosen such that selective conditions (e.g., acidic conditions, basic conditions, catalysis by a nucleophile, catalysis by a Lewis acid, or hydrogenation) are required to remove each, exclusive of other protecting groups in a compound. The conditions required for the addition of protecting groups to amine, alcohol, sulfhydryl, and carboxyl functionalities and the conditions required fortheir removal are provided in detail, for example, in Green, T. W. and Wuts, P. G. M. Protective Groups in Organic Synthesis (2ndEd.), (John Wiley & Sons, 1991) and Kocienski, P. J. Protecting Groups, (Georg Thieme Verlag, 1994).
[0373] Exemplary synthetic methods
[0374] Parmodulins that bind protease-activated receptor 1 (PAR1) and upregulate p-arrestin activity represented by Formulae (l-VII) may be synthesized, for instance, by way of an amide coupling first at the “west end” (wherein the “west end” refers to the G1-X5- portion of compounds represented by Formulae (I-IV)), followed by a nitro group reduction, followed by an amide coupling second at the “east end” (wherein the “east end” refers to the G2-X6- portion of compounds represented by Formulae (l-IV)), such as a process depicted in Scheme 1, below. Alternatively, parmodulins that bind protease-activated receptor 1 (PAR1) and upregulate p-arrestin activity represented by Formulae (l-VII) may be synthesized, for instance, by way of an amide coupling first at the “east end”, followed by a nitro group reduction, followed by an amide coupling second at the “west end”, such as a process depicted in Scheme 2, below.
[0375] Scheme 1. General synthetic scheme for the synthesis of parmodulins represented by Formulae (l-VII), in cases where it is advantageous to functionalize the “west end” of the compound before functionalizing the “east end” of the compound. In US Pat. No. 9,422,262 B2; US Pat. No. 11,130,743 B2.
[0376]
[0377] wherein each R21and R22can be independently selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.ATTORNEY DOCKET NO: 51861-002W02
[0378] Scheme 2. General synthetic scheme for the synthesis of parmodulins represented by Formulae (l-VII), in cases where it is advantageous to functionalize the “east end” of the compound before functionalizing the “west end” of the compound. In US Pat. No. 9,422,262 B2.
[0379]
[0380] wherein each R21and R22can be independently selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
[0381] Parmodulins that bind protease-activated receptor 1 (PAR1) and upregulate p-arrestin activity represented by Formulae (Vlll-X) may be synthesized, for instance, by way of an / V-alkylation first at the “west end”, followed by a nitro group reduction, followed by an amide coupling second at the “east end”, such as a process depicted in Scheme 3, below.
[0382] Scheme 3. General synthetic scheme for the synthesis of parmodulins represented by Formulae (Vlll-X), in cases where it is advantageous to functionalize the “east end” of the compound before functionalizing the “west end” of the compound. In US Pat. No. 9,422,262 B2.
[0383]
[0384] wherein each R22and R23can be independently selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
[0385] Parmodulins that bind protease-activated receptor 1 (PAR1) and upregulate p-arrestin activity represented by Formula (XI) may be synthesized, for instance, by way of a ZnCh-mediated cyclization, followed by an / V-alkylation, such as a process depicted in Scheme 4, below.
[0386] Scheme 4. General synthetic scheme for the synthesis of parmodulins represented by Formula (XI), comprising a ZnCh-mediated cyclization of an appropriate 2-aminobenzonitrile and ketone and the subsequent / V-alkylation. In US Pat. Pub. No. US 2004 / 0147540 A1.
[0387]
[0388] wherein R205can be an alkyl group.
[0389] Parmodulins that bind protease-activated receptor 1 (PAR1) and upregulate p-arrestin activity represented by Formula (XII) may be synthesized, for instance, by way of an / V-acetylation, followed by condensation, such as a process depicted in Scheme 5, below.
[0390] Scheme 5. General synthetic scheme for the synthesis of parmodulins represented by Formula (XII), comprising an / V-acetylation and the condensation of an appropriate acetophenone with aATTORNEY DOCKET NO: 51861-002W02
[0391] hydrazide. In VerPlank, etal. Chemical Genetic Analysis of Platelet Granule Secretion-Probe 1 Probe Reports from the NIH Molecular Libraries Program (2010).
[0392]
[0393] wherein R302can be methyl or trifluoromethyl;
[0394] wherein R303can be selected from the group consisting of optionally substituted alkyl and optionally substituted cycloalkyl; and
[0395] wherein R304can be methyl or hydrogen.
[0396] Examples
[0397] The following examples are put forth so as to provide those of ordinary skill in the art with a description of how the compositions and methods described herein may be used and evaluated and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventor(s) regard as their invention.
[0398] Example 1. Evaluation of selective p-arrestin recruitment by parmodulins and screen compounds of interest.
[0399] Objective
[0400] The objective of this study was to evaluate compounds of interest fortheir ability to selectively increase p-arrestin recruitment through PAR1 rather than through the closely related PAR2 receptor. In addition, certain compounds were assessed to see whether they lead to endothelial cell retraction, which is known to occur following activation by thrombin and certain other proteases, cytokines, or toxins. In the context of neurological disorder(s), PAR1 activation by thrombin is associated with impairment of the blood-brain barrier (BBB), blood-spinal cord barrier (BSCB) and / or blood-nerve barriers (BNBs), neuronal death, neurovascular dysfunction (e.g., in the case of traumatic brain injury), and neurodegenerative diseases. Therefore, PAR1 -p-arrestin signaling can be leveraged to promote barrier- and / or cytoprotective effects.
[0401] Materials and Methods
[0402] PAR1 p-arrestin recruitment assay (Borealis assay, commercially available from Montana Molecular)
[0403] For determination of PAR1 -dependent p-arrestin recruitment, HEK 293T cells in 384 well plates were transfected with PAR1 and the Borealis p-arrestin biosensor, then treated with different concentrations of the compound of interest and the EC20 (160 nM) of the PAR1 agonist TFLLR-NH2. Activation of the p-arrestin-2 biosensor was quantified by its decrease in fluorescence at 509 nm upon activation. By taking measurements prior to and after agonist addition, compounds can be characterized as PAR1- p-arrestin agonists, inverse agonists, antagonists, or positive allosteric modulators, as shown in FIG. 2. An additional assay, described below, was used to confirm that p-arrestin recruitment is selectively dependent on PAR1 and not driven by the closely related receptor PAR2.ATTORNEY DOCKET NO: 51861-002W02
[0404] PAR2 -arrestin recruitment assay (Borealis assay)
[0405] For determination of PAR2-dependent p-arrestin-2 recruitment, HEK293T cells in 384 well plates were transfected with PAR2 and the Borealis p-arrestin-2 biosensor, then treated with different concentrations of the compound of interest and the EC2oofthe PAR2 agonist 2-furoyl-LIGRLO. The PAR2-driven p-arrestin assay kit has been validated and is available from Montana Molecular (#D2090G). In some embodiments, compounds with EC50 < 10 pM (e.g., about 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 210 nM, 220 nM, 230 nM, 240 nM, 250 nM, 260, nM, 270 nM, 280 nM, 290 nM, 300 nM, 310 nM, 320 nM, 330 nM, 340 nM, 350 nM, 360 nM, 370 nM, 380 nM, 390 nM, 400 nM, 410 nM, 420 nM, 430 nM, 440 nM, 450 nM, 460, nM, 470 nM, 480 nM, 490 nM, 500 nM, 510 nM, 520 nM, 530 nM, 540 nM, 550 nM, 560 nM, 570 nM, 580 nM, 590 nM, 600 nM, 610 nM, 620 nM, 630 nM, 640 nM, 650 nM, 660 nM, 670 nM, 680 nM, 690 nM, 700 nM, 710 nM, 720 nM, 730 nM, 740 nM, 750 nM, 760 nM, 770 nM, 780 nM, 790 nM, 800 nM, 810 nM, 820 nM, 830 nM, 840 nM, 850 nM, 860 nM, 870 nM, 880 nM, 890 nM, 900 nM, 910 nM, 920 nM, 930 nM, 940 nM, 950 nM, 960 nM, 970 nM, 980 nM, 990 nM, 1 pM, 1.1 pM, 1.2 pM, 1.3 pM, 1.4 pM, 1.5 pM, 1.6 pM, 1.7 pM, 1.8 pM, 1.9 pM, 2 pM, 2.1 pM, 2.2 pM, 2.3 pM, 2.4 pM, 2.5 pM, 2.6 pM, 2.7 pM, 2.8 pM, 2.9 pM, 3 pM, 3.1 pM, 3.2 pM, 3.3 pM, 3.4 pM, 3.5 pM, 3.6 pM, 3.7 pM, 3.8 pM, 3.9 pM, 4 pM, 4.1 pM, 4.2 pM, 4.3 pM, 4.4 pM, 4.5 pM, 4.6 pM, 4.7 pM, 4.8 pM, 4.9 pM, 5 pM, 5.1 pM, 5.2 pM, 5.3 pM, 5.4 pM, 5.5 pM, 5.6 pM, 5.7 pM, 5.8 pM, 5.9 pM, 6 pM, 6.1 pM, 6.2 pM, 6.3 pM, 6.4 pM, 6.5 pM, 6.6 pM, 6.7 pM, 6.8 pM, 6.9 pM, 7 pM, 7.1 pM, 7.2 pM, 7.3 pM, 7.4 pM, 7.5 pM, 7.6 pM, 7.7 pM, 7.8 pM, 7.9 pM, 8 pM, 8.1 pM, 8.2 pM, 8.3 pM, 8.4 pM, 8.5 pM, 8.6 pM, 8.7 pM, 8.8 pM, 8.9 pM, 9 pM, 9.1 pM, 9.2 pM, 9.3 pM, 9.4 pM, 9.5 pM, 9.6 pM, 9.7 pM, 9.8 pM, 9.9 pM, or 10 pM) in the PAR1 -driven p-arrestin activity assay and an EC50 > 100 pM (e.g., about 100 pM, 110 pM, 120 pM, 130 pM, 140 pM, 150 pM, 160 pM, 170 pM, 180 pM, 190 pM, 200 pM, 210 pM, 220 pM, 230 pM, 240 pM, 250 pM, 260, pM, 270 pM, 280 pM, 290 pM, 300 pM, 310 pM, 320 pM, 330 pM, 340 pM, 350 pM, 360 pM, 370 pM, 380 pM, 390 pM, 400 pM, 410 pM, 420 pM, 430 pM, 440 pM, 450 pM, 460, pM, 470 pM, 480 pM, 490 pM, 500 pM, 510 pM, 520 pM, 530 pM, 540 pM, 550 pM, 560 pM, 570 pM, 580 pM, 590 pM, 600 pM, 610 pM, 620 pM, 630 pM, 640 pM, 650 pM, 660 pM, 670 pM, 680 pM, 690 pM, 700 pM, 710 pM, 720 pM, 730 pM, 740 pM, 750 pM, 760 pM, 770 pM, 780 pM, 790 pM, 800 pM, 810 pM, 820 pM, 830 pM, 840 pM, 850 pM, 860 pM, 870 pM, 880 pM, 890 pM, or 900 pM) in the PAR2-driven p-arrestin activity assay will be considered PAR1 -selective activators of p-arrestin recruitment.
[0406] PAR1 p-arrestin recruitment assay (PATHHUNTER™ assay, commercially available from Eurofins DiscoverX, catalog# 93-0278E2CP0M)
[0407] CHO-K1 epithelial cells stably expressing modified versions of PAR1 and p-arrestin-2 containing complementary portions of a p-galactosidase enzyme were cultured in 384 well plates. The cells were incubated with ligands for 15 min., then treated with 20% effective concentration (EC20) of the PAR1 agonist TFLLR-NH2 for 2 h before addition of reagent cocktail (including luminescent p-galactosidase substrate) and measurement by plate reader.ATTORNEY DOCKET NO: 51861-002W02
[0408] PAR2 p-arrestin recruitment assay (PATHHUNTER™ assay, commercially available from Eurofins DiscoverX, catalog# 93-0235E1CP0M)
[0409] HEK 293 epithelial cells stably expressing modified versions of PAR2 and p-arrestin-2 containing complementary portions of a p-galactosidase enzyme were cultured in 384 well plates. The cells were incubated with ligands for 15 min., then treated with 20% effective concentration (EC20) of the PAR2 agonist SLIGRL-NH2 for 1.5 h before addition of reagent cocktail (including luminescent p-galactosidase substrate) and measurement by plate reader.
[0410] PAR-driven intracellular calcium mobilization ( / Ca2+)
[0411] Further confirmations that compounds of interest selectively act through PAR1 and not PAR2 can be tested with EA.hy926 endothelial cells or a suitable cell line stably or transiently expressing PAR1 and PAR2 fortheir ability to inhibit calcium mobilization induced by a PAR1 agonist (such as SFLLRN-NH2), or a PAR2 agonist (such as 2-furoyl-LIGRLO). Intracellular calcium is measured using Fluo4 / AM loaded into the cells. 8-point concentration-response curves are typically determined (n=2 or more). Adetailed protocol with EA.hy926 cells has been published using a plate reader with 96 well plates, and a similar protocol can be executed with 384 well plates using a plate imager.
[0412] The cells were cultured using the suggested protocol from the manufacturer (ATCC), except that 150 cm2tissue culture flasks were used, and DMEM complete media was prepared as described below. Cells were frozen in 40% fetal bovine serum (FBS), 50% complete media, and 10% DMSO in liquid nitrogen, and used between passages 2 and 11. All manipulations prior to the assays were performed in a sterile laminar flow cell culture hood.
[0413] Complete cell media (for EA.hy926 cells). Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g / L glucose (500 mL) was supplemented with 200 mM L-glutamine (10 mL, 4 mM final cone.), 100 mM sodium pyruvate (2.5 mL, 1 mM final cone.), 7.5% (w / v) sodium bicarbonate (5.0 mL, 0.75 g / L final cone.), 100x penicillin and streptomycin (Corning #30-002-CI, 2.0 mL) and heat inactivated FBS (50 mL). The prepared media was stored in a refrigerator (5 °C) until needed.
[0414] Cell counting was performed with an automated cell counter (Countess, Invitrogen) using Invitrogen cell counting chamber slides and trypan blue stain. All assays were run in 96-well plates (Corning Costar #3603, polystyrene black wall, clear bottom). Cells were imaged with an EVOS Fl inverted microscope. All assays were run on a multimode plate reader (Perkin Elmer EnSpire). Data was exported to Microsoft Excel for nominal processing then analyzed with Graph-Pad Prism (versions 5 or 6).
[0415] Prior to the assay, stock solutions of PAR1 and PAR2 agonists were prepared by dissolving the agonists in 100% H2O (sterile, deionized) to give stock solutions (10 mM, 5 mM, or 1 mM depending on agonist). These were aliquoted into sterile microcentrifuge tubes and stored in a - 30 °C freezer, and thawed before use. Stock solutions of antagonists were prepared by dissolving with 100% DMSO, generally in glass vials, to give stock solutions (31.6 mM, 10 mM, or 1 mM depending on antagonist used) that were stored in the freezer at - 30 °C, and thawed in a desiccator before use. Agonist solutions were prepared as 10 mM stock solutions in 100% water (sterile, deionized). Diluted solutions were then prepared with water to give half log concentrations. Vehicle (diluent) was prepared by mixing 1: 9 DMSO: HBSS-HEPES wash buffer. An aliquot from the antagonist stock solution (in 100% DMSO) was then diluted 10x with vehicle to give a 10% DMSO solution, then subsequent dilutions were made with vehicle to give a consistent concentration of DMSO (10%). Additional details pertaining to the assay protocol forATTORNEY DOCKET NO: 51861-002W02
[0416] measuring endothelial PAR-driven intracellular calcium mobilization are previously described, e.g., in DeRousse etal. Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader. The Journal of Visualized Experiments. 207, e66507 (2024), the contents of which are incorporated herein by reference. Exemplary assay results are previously described, e.g., in Gandhi et al. The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved antiinflammatory activity and stability., Bioorganic & Medicinal Chemistry. 27, (2019), and Gandhi etal. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1 -driven calcium mobilization in endothelial cells. Bioorganic & Medicinal Chemistry. 26, (2018)., the contents of which are incorporated herein by reference.
[0417] Endothelial retraction assay
[0418] EA.hy926 endothelial cells were cultured and treated with a range of parmodulins (10 pM) or vehicle before treatment with thrombin (10 nM) for 30 min. Intercellular gap formation (red areas) was visualized by F-actin staining (phalloidin, green; scale bar = 100 pm), and gap areas were quantified (5 images from each of 3 replicates) with Imaged in an automated fashion. Images of controls and compound 45 treatment are shown in FIG. 3; images from experiments from other parmodulins are omitted.
[0419] Results
[0420] Compounds with EC50 < 10 pM in a PAR1 -driven p-arrestin activity assay and IC50 > 50 pM in a PAR2-driven calcium assay were observed, such as with compound 45 (FIG. 2B, 2C). Unlike with the PAR1 antagonist vorapaxar, which potently inhibits p-arrestin recruitment (FIG. 2A), parmodulins such as compound 45 potentiate (boost) p-arrestin recruitment. Additionally, the PAR2 assay provides an important measure of selectivity, because any compound inactive in the PAR2 assay(s) can be assumed to be inactive as an antagonist at PAR2 and inactive against downstream components of the G protein pathway, including the relevant MAP kinases. It was also observed that compounds of the disclosure inhibit thrombin-induced endothelial cell retraction (FIG. 3), which is indicative that these compounds can be used to increase the integrity of the BBB, BCSB, and / or BNB under post-injury conditions. Without being limited by mechanism, in this way, compounds of the disclosure may be used to treat pain and / or neurological dysfunction.
[0421] Example 2. Evaluation of the analgesic effect of parmodulin treatment in rat spared nerve injury model.
[0422] Objective
[0423] The objective of this study was to evaluate the efficacy of an exemplary parmodulin, compound 45, for treatment of neuropathy in rats following nerve injury surgery. The analgesic efficacy of compound 45 was measured with a Randall-Selitto analgesiometer.
[0424] Materials and Methods
[0425] 8 Sprague-Dawley rats in each group (4 male, 4 female) underwent spared nerve injury surgery or sham surgery, then received 7 daily intraperitoneal doses of vehicle (90:10 PEG 400 (w / 2% w / v TweenATTORNEY DOCKET NO: 51861-002W02
[0426] 80): PBS; 1 mL / kg), or compound 45 (10 mg / kg) in vehicle. Rear paw withdrawal thresholds were measured on Day 9 (2 days after the last dose) with a Randall-Selitto analgesiometer on the side of the surgery (ipsilateral), and also on the opposite (uninjured, contralateral) paw. The spared nerve injury surgical procedure is previously described, e.g., in Decosterd et al. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87, 149-158 (2000), the contents of which are incorporated herein by reference. The methods of use for a Randall-Selitto analgesiometer are previously described, e.g., in Santo-Nogueira, E., et al. A New Approach for the Detection of Neuropathic Pain after Spinal Cord Injury. Journal of Neurotrauma 29, 898-904 (2012), the contents of which are incorporated herein by reference.
[0427] Results
[0428] The parmodulin compound 45 is analgesic in the rat spared nerve injury (SNI) model. Compound 45 (10 mg / kg for 7 days) was measured to greatly attenuate responses (paw withdrawal) in the rat spared nerve injury (SNI) model of neuropathic pain (FIG. 4). Pain responses were inhibited even 2 days after the final dose.
[0429] Example 3. Evaluation of the analgesic effect of parmodulins treatment in streptozotocin-induced diabetic neuropathy mouse model.
[0430] Objective
[0431] Diabetic neuropathy involves sensory neuropathy, which can include either hyperalgesia or hyposensitivity, and early involvement of small nerve fibers, with progressive involvement of motor nerves. The objective of this study would be to evaluate the efficacy of exemplary parmodulins, or other compounds of the disclosure, for treatment of neuropathy in a streptozotocin-induced diabetic neuropathy model in mice. Protocols for generating and characterizing the streptozotocin-induced neuropathy model in mice are described e.g., in Shavit-Stein, E. etal. Treatment of Diabetic Neuropathy with A Novel PAR1-Targeting Molecule. Biomolecules 10, 1552 (2020), the contents of which are incorporated herein by reference.
[0432] Materials and Methods
[0433] Induction of diabetic neuropathy with streptozotocin
[0434] Diabetes may be induced by a single (150 mg / kg) intraperitoneal (IP) injection of streptozotocin (STZ, S0130, Sigma-Aldrich, St. Louis, MO, USA, 0.1 M sodium citrate buffer, pH 4.5). Glucose levels may be measured by a commercial glucometer device on three repeated occasions within a week from STZ injection and mice may be considered hyperglycemic when glucose levels are above 250 mg / dl. Body weight may be measured daily.
[0435] Assessment of Neuropathic Pain
[0436] To measure changes in the tactile sensitivity of the hind paw, mice would be placed individually in chambers placed on a mesh floor. Calibrated von Frey filaments would be applied vertically to the plantar surface of the hind paw to bend the filament for several seconds. A swift withdrawal may be considered a positive response. The tactile stimulus producing a 50% likelihood of withdrawal response would be calculated by using the method known in the art. To measure the mechanical nociceptive threshold, aATTORNEY DOCKET NO: 51861-002W02
[0437] pressure stimulus on the hind paw using a Randall-Selitto analgesiometer would be applied. The device would be activated to apply a constantly increasing force. When the animal displayed a paw withdrawal response, the device would instantly stop to register the animal’s withdrawal threshold. The investigators testing the nociceptive behaviors would be blinded to the treatment conditions. Other exemplary assessments of neuropathic pain are described herein (see section on Preclinical Pain Assessment).
[0438] Thermal Sensory Function Evaluation
[0439] Sensory function may be evaluated by thermal response on a hot plate at day 30 following STZ injection. Animals may be placed in a perspex cylinder on a heated stage maintained at 50 ± 1 ° C. Time to heat response indicated by hind paw licking, shaking or jumping may be measured. A maximum on-plate time would be set to 30 seconds to prevent skin injury.
[0440] Projected Results
[0441] Astreptozotocin-induced diabetic neuropathy mouse model may exhibit greatly reduced mechanical and thermal hyperalgesia after administration of a compound of the disclosure, such as a parmodulin.
[0442] Example 4. Evaluation of parmodulin treatment in genetic type 2 diabetic (T2D) mouse neuropathy model.
[0443] Objective
[0444] The objective of this study would be to evaluate the efficacy of exemplary parmodulins, or other compounds of the disclosure, for treatment of neuropathic pain and neural loss in genetic type 2 diabetic (T2D) neuropathy mouse models. Models of T2D have been developed using rodents with mutations involving the hormone leptin (e.g., ob / ob mice) or its receptor (e.g., db / db mice). These mutations result in hyperphagia and consequent obesity, hyperglycemia, and reduced insulin sensitivity. These models can optionally be combined with high fat diets to give rodents with varying levels of neuropathy, including hyperalgesia and allodynia. These models have been reviewed, e.g., by O’Brien, RD. etal. in Mouse Models of Diabetic Neuropathy, ILAR J 54, 259-272 (2014), the contents of which are incorporated herein by reference.
[0445] Materials and Methods
[0446] Animal Care and Treatment
[0447] C57BL / KsJm / / _epfcto (db / db) mice and their normoglycemic heterozygous littermates would be housed, fed, and treated with exemplary parmodulins. Exemplary parmodulins would be starting at 7 weeks of age until 32 / 33 weeks of age. Blood-glucose levels, body weight, and sensory thresholds would be analyzed at regular intervals between ages 5 / 6 and 32 / 33 weeks of age.
[0448] Assessment of Neuropathic Pain
[0449] Pain assessments may include, but are not limited to, determining mechanical allodynia threshold using von Frey monofilaments, mechanical hyperalgesia using the pin-prick test, and cold allodynia by applying a drop of acetone solution. Animals may be placed in transparent plastic domes on a metal mesh floor with a hole-size 2 x 3 mm. After a 30- min habituation period, for the tactile allodynia test the threshold for hind paw withdrawal (both sides) may be measured by graded-strength von FreyATTORNEY DOCKET NO: 51861-002W02
[0450] monofilaments (0.4, 0.6, 1.0, 1.4, 2.0, 4.0, and 6.0 g). For mechanical hyperalgesia, the animals may be placed on an elevated grid, and a pin-prick test may be performed using a 27-gauge needle. The central part of the plantar surface of the hind paw may be briefly stimulated with an intensity that would be sufficient to indent but not penetrate the skin. There would be a ~5-minute time delay between two adjacent stimuli to the same animal. A positive response would be defined as withdrawing, lifting, shaking, or licking the hind paw, and would be measured by determining the number of responses to five test stimuli. For the cold allodynia test, a drop of acetone solution would be carefully applied onto the central plantar surface of the paw, using a blunt needle connected to a syringe. There would be a ~2-minute time delay between two adjacent stimuli, and the number of responses would be calculated in the same way as the pin-prick test. Other exemplary assessments of neuropathic pain are described herein (see section on Preclinical Pain Assessment).
[0451] Electrophysiology
[0452] For in vivo experiments, the sciatic nerve may be exposed, and the impulse conduction velocity calculated from the time-shift (At) of the responses of the gastrocnemius muscle to electrical stimulation at two locations of the nerve. For the in vitro experiments, a section of the nerve may be excised and transferred into a temperature-controlled recording chamber. The distance between stimulating and recording electrodes would be variable and measured with a caliper, and action currents would be sampled at 100 kHz. The conduction velocity would be calculated from the time from stimulation artifact to peak of the compound action potential. The in vivo conduction velocity experiments would be carried out at ~34 °C, whereas the in vitro experiments would be mainly done at room temperature. To compare the conduction velocity of different fiber size classes, time from stimulation artifact to the trajectory-baseline crossing would be measured.
[0453] Immunohistochemistry
[0454] Animals would be deeply anesthetized (e.g., with sodium pentobarbital) and fixed by vascular perfusion with formalin. The L5 dorsal root ganglia may be dissected, frozen, and cut in a cryostat. The sections may be incubated with various antibodies / antisera and reagents. The sections may be analyzed in a confocal scanning microscope. For quantitative evaluation of NPs, the percentage and intensity of IR dorsal root ganglia NPs would be counted. The size distribution of neuron profiles may be measured using the Nikon Eclipse E 600 fluorescence microscope with Wasabi Image Software.
[0455] Projected Results
[0456] T2D diabetic neuropathy mice models may exhibit greatly reduced mechanical allodynia, mechanical hyperalgesia, and cold allodynia after administration of compounds of the disclosure, such as parmodulins. Treated animals may also experience decreased neuron loss and improvement in neuron impulse conduction compared to untreated controls, which may be measured by immunohistochemistry and electrophysiology tests, respectively.
[0457] Example 5. Evaluation of the analgesic effect of parmodulin treatment in rat following spinal nerve ligation.
[0458] ObjectiveATTORNEY DOCKET NO: 51861-002W02
[0459] The objective of this study would be to evaluate the efficacy of exemplary parmodulins, or other compounds of the disclosure, for the treatment of neuropathy in rats following spinal nerve ligation. Nerve injury can result in impairment of the blood-spinal cord barrier (BSCB), and long-lasting behavioral signs of mechanical allodynia, heat hyperalgesia, cold allodynia, and pain. Effective treatment with parmodulins following spinal nerve ligation can be measured by decreased BSCB permeability, as indicated by degree of IgG immunolabeling in the spinal cord (see Materials and Methods below), and / or decreased hyperalgesia, as measured by von Frey thresholds.
[0460] Materials and Methods
[0461] Characterization of BSCB integrity
[0462] Under anesthesia, the spinal nerve of one side of a rat may be ligated in a manner known by one skilled in the art. Sham surgery would be the same surgical procedures without any nerve ligation. In separate groups of rats, behavioral sensitivity can be measured, and spinal cord tissue can be harvested on either day 1 or day 7 after injury to define the temporal pain and BSCB responses. A tester blinded to the procedure and group designation can measure mechanical hyperalgesia as a measure of pain on days 1, 3, 5 and 7 as well as baseline (day 0) for a subset of the rats. For rats with tissue harvested on day 1 behavioral testing occurred on days 0 and 1. Hyperalgesia can be quantified as the forepaw withdrawal threshold to an applied mechanical stimulus. The threshold can be recorded as the lowest filament strength out of a series of increasing von Frey filaments that elicited a withdrawal of the forepaw upon stimulation. Thresholds for each rat on each day would be determined as the average of three rounds. Paw withdrawal thresholds from the rats that would be harvested on day 1 would be averaged for each group on each day and would be compared using two-way repeated measures ANOVA (group x day) with post-hoc Tukey’s Honestly Significant Difference (HSD) Test. Blood can be collected (0.5ml) from the tail vein before surgery (baseline) and on day 1 after surgery from a subset of rats undergoing either 15 minute, 3 minute or 0 minute (sham) spinal nerve injury. Serum analytes can be separated and assayed for a panel of 23 pro- and anti-inflammatory cytokines and chemokines using a multiplex beadbased Luminex assay kit (e.g., L80-01 V11S5; Bio-Rad). Concentrations on day 1 can be normalized to baseline levels and correlated to the normalized paw withdrawal threshold at day 1 for each rat. Each set of bivariate data (normalized threshold versus normalized cytokine concentration) can be fit with a linear regression and those cytokines that strongly (R2>0.5) and significantly correlate (p-value < 0.05) to paw withdrawal threshold would be noted. Methods and details for spinal nerve ligation surgery and characterization of BSCB integrity are described in detail, e.g., in Xie etal. The effect of lumbar sympathectomy in the spinal nerve ligation model of neuropathic pain. The Journal of Pain 2, 270-278 (2001) and Smith, J. R. etal. Salmon-derived thrombin inhibits development of chronic pain through an endothelial barrier protective mechanism dependent on APC. Biomaterials 80, 96-105 (2015), the disclosures of which are incorporated herein by reference.
[0463] Measuring Mechanical Hyperalgesia & Vascular Permeability
[0464] Parmodulins can be administered beginning at 1 hour after the painful spinal nerve ligation surgery, or optionally beginning at a later time. Mechanical hyperalgesia can be used to quantify behavioral sensitivity in the ipsilateral forepaw before surgery (day 0) and on day 1 after surgery. The paw withdrawal thresholds for the different groups described above can be compared with a suitable statisticalATTORNEY DOCKET NO: 51861-002W02
[0465] test. As above, fixed spinal cord tissue would be harvested at day 1 and immunolabeled for IgG in the bilateral dorsal horns of the spinal cord to evaluate effects of a test compound on BSCB permeability. The percent positive labeling of spinal IgG can then be compared between groups.
[0466] Projected Results
[0467] Treatment with compounds of the disclosure, such as parmodulins, following spinal nerve ligation may result in decreased BSCB permeability, as indicated by degree of IgG immunolabeling in the spinal cord, and / or decreased mechanical hyperalgesia, as measured by von Frey thresholds, in comparison with vehicle treated control mice.
[0468] Example 6. Treatment with effective dosage of parmodulins to an animal subject suffering from neuropathic pain.
[0469] Objective
[0470] Utilizing the compounds disclosed herein, a scientist or physician of skill in the art can treat an animal subject, so as to reduce or alleviate neuropathic pain. Exemplary preclinical models of neuropathic pain include, but are not limited to, the spared nerve injury, spinal nerve ligation, chronic constriction injury, streptozotocin-induced diabetic neuropathy, chemotherapy-induced peripheral neuropathy, and reserpine-driven fibromyalgia models. Effective alleviation of pain can be measured through a wide range of pain assessments, including, but not limited to, the Randall-Selitto analgesiometer, Von Frey fiber test, behavioral tests for motor and / or sensory function (e.g., gait analysis, burrowing behavior), cold allodynia (e.g., acetone test) and / or hot plate sensitivity.
[0471] Materials and Methods
[0472] Induction of diabetic neuropathy with streptozotocin
[0473] The STZ-induced rat model is a commonly used model of diabetic neuropathy. STZ, an alkylating and antimicrobial agent, selectively destroys pancreatic beta cells through DNA alkylation. Typically, diabetes can be induced by a single intraperitoneal or intravenous injection of STZ at a relatively high dose. This leads to prolonged hyperglycemia, hypoinsulinemia, and abnormal glucose metabolism, which may cause the degeneration of neurons. Decreases in neurotrophic factors occur in STZ-induced diabetic animals, such as mice or rats, that parallel those in human patients with diabetic neuropathy, and this, in turn, exacerbates the degeneration of neurons. Slowing of nerve conduction velocity (NOV), a conventional electrophysiological parameter that reflects the severity of nerve dysfunction, also occurs in STZ-induced diabetic animals as in patients with diabetic neuropathy. In addition, STZ-induced diabetic rats show neuropathic pain, characterized by mechanical and thermal allodynia, one of the symptoms of diabetic neuropathy. Gabapentin, pregabalin, amitriptyline, mexiletine, and morphine, but not diclofenac, inhibit allodynia in a rodent model of STZ-induced diabetic neuropathy, suggesting that the STZ model is suitable for evaluating the clinical potential of compounds for treating painful diabetic neuropathy.
[0474] An exemplary protocol for induction of diabetes in mice involves a single (150 mg / kg) intraperitoneal (IP) injection of streptozotocin (STZ, S0130, Sigma-Aldrich, St. Louis, MO, USA, 0.1 M sodium citrate buffer, pH 4.5). Glucose levels may be measured by a commercial glucometer device on three repeated occasions within a week from STZ injection and mice would be considered hyperglycemic when glucose levels are above 250 mg / dl.ATTORNEY DOCKET NO: 51861-002W02
[0475] Induction of chemotherapy-induced peripheral neuropathy
[0476] Chemotherapy-induced peripheral neuropathy (CIPN) may be induced with chemotherapeutic agents, such as paclitaxel, in animal models, such as rats or mice. As a non-limiting example, mice can be dosed intraperitoneally or intravenously with paclitaxel to induce CIPN. Exemplary methods of treatment involve repeat intraperitoneal or intravenous injections of paclitaxel to simulate chemotherapeutic treatment used in human subjects. Doses of paclitaxel typically fall within the range of 3-30 mg / kg when delivered intravenously or intraperitoneally.
[0477] Induction of Reserpine-driven fibromyalgia
[0478] Fibromyalgia is a prevalent and burdensome disorder characterized by chronic widespread pain. The complex physiopathology of fibromyalgia can be modeled as described in detail, e.g., in Nakagura et al. Biogenic amine depletion cause chronic muscular pain and tactile allodynia accompanied by depressions putative animal model of fibromyalgia. Pain 146, 26-33 (2009), as disclosed by reference herein. Repeated administration of reserpine (e.g., 1 mg / kg subcutaneously once daily, for three consecutive days) may cause a significant decrease in the muscle pressure threshold and tactile allodynia, which may be sustained for 1 week or more in both male and female rats. An exemplary protocol would involve administering subcutaneous reserpine (1 mg / kg, once daily) by injection over the flank and repeatedly for 3 consecutive days, with varied sites of injection at the flank. Reserpine may be diluted in glacial acetic acid to a final concentration of 0.5% acetic acid in distilled water. The diluent may be used as a vehicle in the untreated group. Animals from the normal group may receive the same volume of vehicle, but they would not be administered reserpine.
[0479] Chronic Constriction Injury (CCI)
[0480] One of the most widely used models of peripheral nerve damage is unilateral sciatic nerve chronic constriction injury (CCI). CCI is performed under anesthesia. Exemplary methods involve, an approximately 3-cm long blunt dissection made into the skin overlying the area between the gluteus and biceps femoris muscles, and the common sciatic nerve of the hind paw is exposed at the mid-thigh level. Approximately 7 mm of the nerve is freed, proximal to the sciatic trifurcation, and four or three loose ligatures (about 1 mm spacing) of 4-0 chromic guts (or 4-0 silk) are placed around the sciatic nerve until a brief twitch is observed. The wound is closed with sutures in the muscle and staples in the skin. The animal is then allowed to recover from surgery for 24 hrs before pain hypersensitivity testing begins (see disclosed section on Preclinical Pain Assessment).
[0481] Spinal Nerve Ligation Model
[0482] SNL is a known model of the peripheral nerve injury that produces incomplete denervation of the sciatic nerve sensory territory through selective damage of a subset of spinal nerves forming the sciatic nerve. An exemplary protocol in rats involves anesthetizing and placing rats in the prone position to shave the lower back. Thereafter, a 2-cm long incision may be made at the level of the posterior iliac crest to access the left lumbar spinal nerves. L5 and L6 spinal nerves may be identified and carefully dissected free from the adjacent L4 spinal nerve, and then, tightly ligated distal to the dorsal root ganglia (DRG) using 6-0 silk suture. Anticipated operation results include long-lasting behavioral alterations such as mechanical allodynia, heat hyperalgesia, cold allodynia, and ongoing pain.ATTORNEY DOCKET NO: 51861-002W02
[0483] Projected Results
[0484] After administration of compounds of the disclosure, such as parmodulins, these animals may exhibit greatly reduced neuropathic pain symptoms as measured by pain assessments, including, but not limited to, the exemplary pain assessments described herein.
[0485] Example 7. Treatment with effective dosage of parmodulins to an animal subject suffering from inflammatory pain.
[0486] Objective
[0487] Utilizing the compounds disclosed herein, a practitioner of skill in the art can treat an animal subject, so as to reduce or alleviate inflammatory pain. Exemplary preclinical models of inflammatory pain may involve the administration of Complete Freund’s Adjuvant (CFA) or Carrageenan in an animal subject, such as a rat or mouse. Pain, as well as these pathophysiological characteristics can be measured as described in detail, e.g., in Noh etal. Effects of difference doses of complete Freund’s adjuvant on nociceptive behavior and inflammatory parameters in polyarthritic rat model mimicking rheumatoid arthritis. PLOS ONE 16, e0260423 (2021), as disclosed by reference herein. One of the best characterized acute inflammatory models includes the CFA-induced rodent model. Effective alleviation of inflammatory pain can be measured through a wide range of pain assessments, including - but not limited to - the Randall-Selitto analgesiometer, Von Frey fiber test, behavioral tests for motor and / or sensory function (e.g., gait analysis, burrowing behavior), cold allodynia (e.g., acetone test) and / or hot plate sensitivity. In addition, other exemplary physiological end-point measurements may involve, but are not limited to, cytokine / chemokine analysis, hematological analysis immunohistochemistry, and biochemical analysis.
[0488] Materials and Methods
[0489] Complete Freund’s Adjuvant (CFA) Inflammatory pain model
[0490] Complete Freund’s adjuvant (1 mg / ml of Mycobacterium tuberculosis, heat killed and dried) can be obtained from Sigma and diluted appropriately with saline for administration. An exemplary protocol for a CFA rat model involves placing the rat in a temporary restraint with inhalational anesthesia until the rat is unconscious. For example, typically a concentration of 5% isoflurane (v / v) would be sufficient to induce anesthesia. Once animals have lost their righting reflex, they would remain anesthetized for about 15-20 seconds, which is adequate time to clean and inject the paw. The plantar surface on the footpad would be thoroughly cleaned with betadine and 70% ethanol. Then, the needle may be inserted, bevel up, into the metatarsal region of the hindpaw (just proximal to the distal calluses). Additional details and experimental considerations regarding the administration of CFA are described in detail, e.g., in Fehrenbacher ef al. Models of Inflammation: Carrageenan- or Complete Freund’s Adjuvant-Induced Edema and Hypersensitivity in the Rat. Current protocols in pharmacology. 5, Unit5.4 (2012), as disclosed by reference herein.
[0491] Projected Results
[0492] Preclinical animal models suffering from inflammatory pain, such as the CFA model, may exhibit greatly reduced hyperalgesia (von Frey thresholds), measured shortly after administration of compounds of the disclosure, such as parmodulins, compared to the vehicle-treated controls. Treated animals mayATTORNEY DOCKET NO: 51861-002W02
[0493] also experience smaller pathophysiological changes, such as, but not limited to, differences in cytokine / chemokine serum levels, degree of immune cell infiltration, and barrier permeability.
[0494] Example 8. Oral administration of therapeutic parmodulins to a patient suffering from pain.
[0495] Objective
[0496] Existing methods and compositions for pain management, such as gabapentinoids, often have deleterious side effects, such as vertigo, fatigue, and weight gain. Compounds of the disclosure may additionally represent a novel class of analgesic drugs that could minimize abuse potential, when compared to drugs used in acute pain treatment, such as opiates. Using conventional medical techniques known in the art, a therapeutic or diagnostic agent (e.g., parmodulin), can be orally administered to a patient suffering from pain. For instance, a patient suffering from neuropathy, for example, resulting from diabetes, can be administered a parmodulin orally.
[0497] Materials and Methods
[0498] According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, so as to reduce or alleviate neuropathic symptoms, for example resulting from neuropathic complications of diabetes. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject, and it will vary with the disease, age, weight, and response of the patient. The appropriate dosage can be determined by one skilled in the art.
[0499] The parmodulin can be administered to the patient at an amount sufficient to treat one or more of the pathological features of a disease, following which, the responsiveness to treatment can be measured. Pain intensity experienced by patients can be ranked clinically using pain scales to assess acute, chronic and neuropathic pain. Pain scales include, but are not limited to, the Numerical Rating Score (NRS), the Neuropathic Scale (NPS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS). Methods for determining an NRS, an NPS, and a LANSS are described in detail, e.g., e.g., in McCaffery etal., Pain: Clinical Manual for Nursing Practice. (Baltimore, 1993) or May, S etal. Diagnosis and assessment of neuropathic pain. F1000 Medicine Reports 1 (2009), the disclosures of which are incorporated herein by reference as it pertains to methods for obtaining and evaluating an NRS, an NPS, and a LANSS.
[0500] Projected Results
[0501] Patients suffering from neuropathic pain may exhibit greatly reduced neuropathic pain symptoms as measured by clinical pain assessments, including but not limited to the exemplary clinical pain assessments stated in the disclosure.
[0502] Example 9. Protection of HT22 cells from thromboinflammation and / or excitotoxicity.
[0503] HT22 cells are an immortalized mouse hippocampal neuronal cell line commonly used to study neuronal diseases. HT22 cells may be cultured in 96 well plates according to published protocols, such as by Aguayo, L. G. et al. in Boldine Attenuates Synaptic Failure and Mitochondrial Deregulation in Cellular Models of Alzheimer’s Disease. Frontiers in Neuroscience 15, 617821 (2021), the contents of which are incorporated herein by reference. Cells can be treated with a compound disclosed herein (e.g., a parmodulins) and optional PAR1 activator, such as thrombin or the peptide TFLLRN-NH2, thenATTORNEY DOCKET NO: 51861-002W02
[0504] optionally subjected to conditions of excitotoxicity by elevating the concentration of glutamate to 5 mM for 24 hours. After 24 hours, cell viability may be measured e.g., by measurement of lactate dehydrogenase (LDH) release into the supernatant, by ATP levels from lysed cells using commercial kits (e.g., CELLTITER-GLO®), or by the use of DNA-binding dyes (e.g., 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT)) that label dead or dying cells with compromised membranes.
[0505] Alternatively, neurite fragmentation, an important measure of neurodegeneration, can be measured by culturing neurons on optical plates or slides for the above experiments, then calculating a degeneration index (DI) using published protocols. For example, Kraemer, B. R. etal. Quantification of Neurite Degeneration with Enhanced Accuracy and Efficiency in an In Vitro Model of Parkinson’s Disease. eNeuro, 9, ENEURO.0327-21.2022 (2022), the disclosure of which is incorporated herein by reference, described the immunofluorescent labeling of neurites and neurite fragments with βIII-tubulin primary antibodies and image analysis of intact neurites and fragments. Additionally, injury markers such as ATF-3 can be measured using established methods (e.g., Western blot).
[0506] Example 10. Protection of mouse primary cortical neurons from thromboinflammation and / or excitotoxicity.
[0507] Primary prefrontal cortical neurons can be isolated from embryonic C57BL mice and cultured according to published protocols e.g., in Hilgenberg, L. G. W.; Smith, M. A., Preparation of Dissociated Mouse Cortical Neuron Cultures. Journal of Visualized Experiments, 10, 562 (2007), the disclosure of which is incorporated herein by reference, and seeded in a 96-well plate for 7-10 days. The resulting neurons may be treated with a compound disclosed herein (e.g., a parmodulins) and optional PAR1 activator, such as thrombin or the peptide TFLLRN-NH2, then optionally subjected to conditions of excitotoxicity by elevating the concentration of glutamate to 0.625 mM for 24 hours. After 24 hours, cell viability, neurite fragmentation, and / or injury markers can be measured e.g., as described above.
[0508] Example 11. Protection of rat hippocampal neurons from thromboinflammation and / or excitotoxicity
[0509] Rat hippocampal neurons may be isolated from E17-19 SD rats and cultured according to published protocols, such as in Ferrer-Montiel, A. etal., Selected peptides targeted to the N-methyl-D-aspartate (NMDA) receptor channel protect neurons from excitotoxic death, Nature Biotechnol. 16, 286 (1998), the disclosure of which is incorporated herein by reference. 30,000 cells / well / 100 pL may be seeded into 96-well plates. The plates are incubated for 2 days, then on day 3 cytosine arabinoside (10 pM) may be added to kill proliferative cells. On day 4, half of the medium in each well may be exchanged for fresh Neurobasal complete medium (Neurobasal + 1XB27 + 1XPS). On day 10, the primary hippocampal neurons may be washed twice with 100 pL / well Hank’s balanced salt solution (HBSS) containing 2.4 mM CaCI2 and 20 mM HEPES without magnesium, incubating for 15 min at 37 °C between each wash. The resulting neurons may be treated with a parmodulin and optional PAR1 activator, such as thrombin or the peptide TFLLRN-NH2, then optionally subjected to conditions of excitotoxicity by changing the media to HBSS containing 2.4 mM CaCI2 and 20 mM HEPES without magnesium, with added 10 pM NMDA and 10 pM glycine, and the parmodulin and optional PAR1 activator. The cells may be incubated under these conditions for 20 minutes at 37 °C, then the buffer would be changed to Neurobasal complete medium containing parmodulin and optional PAR1 activator.ATTORNEY DOCKET NO: 51861-002W02
[0510] After incubating for 24 hours at 37 °C, cell viability, neurite fragmentation, and / or injury markers can be measured, e.g., as described above.
[0511] Example 12. Protection of neurons from physical injury under inflammatory conditions.
[0512] N2a cells (a mouse neuroblastoma cell line) have been used extensively in neuroscience research. For greater biorelevance, N2a cells can be optionally differentiated into neuron-like cells using either retinoic acid (RA) for cortical type neurons or dibutyryl-cAMP (dcAMP) for dopaminergic neurons on BIOFLEX® silastic membrane plates. A suitable instrument, such as The Cell Injury Controller II, may be used to injure neuron-like cells grown on a 6 well plate with silastic membrane substrate. A biaxial stretch injury may be induced, resembling the physical stress experienced by brain cells during a traumatic brain injury. Cells can be injured 4xwith an hour separating each injury. Cells can be treated before or after injury with a parmodulin and optional PAR1 activator (e.g., thrombin) to mimic an inflammatory state. Cell viability, neurite fragmentation, and / or injury markers can be measured, e.g., as described above.
[0513] Example 13. Protection of neurons from metabolic injury under inflammatory conditions.
[0514] A suitable cultured cell line or primary neuron (e.g., HT22, PC12, or primary rodent cortical neurons) may be treated with a parmodulin and optional PAR1 activator (e.g., thrombin), and subjected to hyperglycemic conditions for an extended period (for example, 96 hours in the case of PC12 cells, as reported by Martinoli et al. Quercetin and Sesamin Protect Neuronal PC12 Cells from High-Glucose-Induced Oxidation, Nitrosative Stress, and Apoptosis. Rejuvenation Research 15, 322 (2012), the disclosure of which is incorporated herein by reference. Alternatively, cells can be subjected to conditions of low oxygen followed by regular oxygen to mimic the conditions of hypoxia-reperfusion injury and / or stroke. Cell viability, neurite fragmentation, and / or injury markers can be measured as described above.
[0515] Example 14. Protection of neurons from chemical or neurotoxin injury under inflammatory conditions.
[0516] A suitable cultured cell line or primary neuron (e.g., HT22, PC12, or primary rodent cortical neurons) may be treated with a parmodulin and optional PAR1 activator (e.g., thrombin), and subjected to a chemotoxic agent (e.g., paclitaxel, cisplatin, bortezomib), cytokine or inflammatory mediator (e.g., lipopolysaccharide (LPS), TNF-a), or neurotoxic peptide (e.g., amyloid beta peptide (1-42)) for an optimized time period, such as described in Butterfield, D. A. etal. Protective Effect of Quercetin in Primary Neurons Against Ap(1 -42): Relevance to Alzheimer's Disease. Journal of Nutritional Biochemistry 20, 269 (2009), the disclosure of which is incorporated herein by reference. Cell viability, neurite fragmentation, and / or injury markers can be measured as described above.
[0517] Example 15. Protection of human induced-pluripotent stem cell-derived neurons
[0518] Similar to the above examples, commercial human induced-pluripotent stem cell-derived (iPSC) neurons (e.g., iCell motor neurons from FujiFilm Cellular Dynamics) can be subjected to conditions of thromboinflammation, excitotoxicity, physical injury, and / or chemical or neurotoxin injury in the presence of a parmodulin and optional PAR1 activator. Cell viability, neurite fragmentation, and / or injury markers can be measured as described above.ATTORNEY DOCKET NO: 51861-002W02
[0519] Example 16. Inhibition of activation of microglia under inflammatory conditions.
[0520] Cultured microglial cells or cell lines, such as BV2, can be activated by inflammatory agents such as lipopolysaccharide (LPS) or TNF-a. This activation leads to the release of cytokines such as IL-1 p, IL-6, and TNF-a, which can be measured by standard ELISA or binding assays (as described for example in Li, Y. et al. Interference with Protease-activated Receptor 1 Alleviates Neuronal Cell Death Induced by Lipopolysaccharide-Stimulated Microglial Cells through the PI3K / Akt Pathway. Scientific Reports 6, 38247 (2016), the disclosure of which is incorporated herein by reference. The inhibition ofthis activation can be measured in the presence of a suitable parmodulin and an optional exogenous PAR1 activator, such as thrombin, which itself is pro-inflammatory.
[0521] Example 17. Inhibition of activation of astrocytes under inflammatory conditions.
[0522] Astrocytes can be isolated from rodents according to published protocols, and activated by inflammatory agents such as thrombin, as described in the literature, for example in Wang, Y. etal.
[0523] Thrombin induces morphological and inflammatory astrocytic responses via activation of PAR1 receptor.
[0524] Cell Death Discovery 8, 189 (2022), the disclosure of which is incorporated herein by reference. This activation leads to measurable morphological changes in the astrocytes (a decrease in cells with stellate morphology), and the release of cytokines such as IL-1 p, IL-6, and TNF-a, which can be measured by standard ELISA or binding assays. The inhibition of this activation can be measured in the presence of a suitable parmodulin and an exogenous PAR1 activator, such as thrombin, if it is not already included in the experiment.
[0525] Example 18. Synthesis of select compounds of the disclosure
[0526] The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and / or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.
[0527] Scheme 6. Synthesis of compound 1.
[0528]
[0529] / V-(3-nitrophenyl)butyramide (164)
[0530] 3-Nitroaniline (6.00 g, 43.4 mmol) was sealed in a flask with stir bar under nitrogen and dissolved with dichloromethane (145 mL). The solution was cooled on ice before (i-Pr)2NEt (8.35 ml, 47.8 mmol) and butyryl chloride (5.00 ml, 47.8 mmol) were added. The flask was removed from the ice and stirred for 16 h. The reaction was then diluted with dichloromethane and aqueous 1 M HCI, the layers wereATTORNEY DOCKET NO: 51861-002W02
[0531] separated, and the combined organics were washed again with 1 M aq. HCI, then twice with half-saturated aq. NaHCO3, then brine. The organic phase was dried over MgSO4, filtered, and concentrated, yielding a yellow oil (9.04 g, 99%). LRMS (ESI⁻) (M - H): 207.06.1H NMR (300 MHz, CDCl3): δ8.45 (brs, 1H), 8.19 (br s, 1H), 7.94 (comp, 2H), 7.46 (app t, J = 8.2 Hz, 1H), 2.43 (t, J = 7.4 Hz, 2H), 1.77 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). MS (ESI⁻): 207.06. The crude oil was used without further purification in the subsequent reaction.
[0532]
[0533] / V-(3-aminophenyl)butyramide (165)
[0534] A solution of / V-(3-nitrophenyl)butyramide (8.60 g, 41.3 mmol) in methanol (207 mL) was divided between two 500 mL flasks with stir bars. Each flask was flushed well with nitrogen, then 5% palladium on carbon (4.40 g, 2.065 mmol) was added, half to each flask. A 3-way adapter with a large hydrogen-filled balloon was attached to each flask, and the reactions were evacuated and back-filled with hydrogen five times, while stirring vigorously. The reactions were then stirred for 16 h, then filtered through a funnel packed with Celite. The filter cake was washed with methanol, and the filtrate was concentrated, redissolved with dichloromethane, then purified by column chromatography (EtOAc / hexanes gradient) to yield a white solid after precipitating from hexanes (5.87 g, 80%).1H NMR (300 MHz, CDCl3): δ 7.19 (brs, 2H), 7.06 (t, J = 8.0 Hz, 1 H), 6.66 (d, J = 7.8, 1 H), 6.42 (d, J = 6.9 Hz, 1 H), 3.69 (s, 2H), 2.30 (t, J = 7.4 Hz, 2H), 1.84-1.61 (m, 3 H), 0.99 (t, J = 7.4 Hz, 3H). MS (ESI⁺) (M + H): 179.18.
[0535]
[0536] 2-bromo- / V-(3-butyramidophenyl)benzamide (1)
[0537] 2-Bromobenzoic acid (259 mg, 1.29 mmol) was sealed in a flask with stir bar under nitrogen, then dissolved with dichloromethane (7.5 mL) and cooled on ice. Oxalyl chloride (113 pL, 1.29 mmol) and N, N-dimethylformamide (4 pL, 0.06 mmol) were added, then the reaction was removed from the ice bath and stirred for 3 h with a vent to an oil bubbler. / V-(3- Aminophenyl)butyramide (200 mg, 1.12 mmol) was then added, followed by pyridine (209 pL, 2.58 mmol). After 18 h, LC-MS analysis showed complete consumption of the amine reactant. The reaction was diluted with ethyl acetate (40 mL) and 1 M aq. HCI (40 mL), then the layers were separated, and the organic phase was washed again with aqueous HCI, then twice with half-saturated aqueous NaHCO3, then brine. The organics were dried over Na2SO4, filtered, and concentrated to a colorless oil. The oil was redissolved with dichloromethane, then hexane was added to induce the precipitation of an amorphous solid. The suspension was concentrated and dried under hi-vacuum to yield the title compound (382 mg, 94%).1H NMR (300 MHz, CDCl3): δ7.95 (s, 1 H), 7.75 (s, 1 H), 7.62 (app t, J = 7.6 Hz, 2H), 7.37 (comp, 6H), 2.31 (t, J = 7.4 Hz, 2H), 1.74 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H).13C NMR (75 MHz, CDCl3): δ 171.3, 165.6, 138.8, 138.1, 137.7, 133.6, 131.6, 129.7, 127.8, 119.3, 116.0, 115.5, 111.1, 39.7, 19.0, 13.7. HRMS (ESI⁺): calculated mass for C17H17BrN2O2[M+H] 361.0546, found 361.0532.ATTORNEY DOCKET NO: 51861-002W02
[0538] Scheme 7. Synthesis of compound 3. See Scheme 2.
[0539]
[0540] 2-bromo- / V-(3-nitrophenyl)benzamide (166)
[0541] 2-Bromobenzoic acid (5.02 g, 25.0 mmol) was sealed in a 250 mL flask with stir bar under nitrogen. Dichloromethane (72 mL) was then added and the solution was cooled on ice. Oxalyl chloride (2.19 ml, 25.0 mmol) and / V, / V-dimethylformamide (17 pL, 0.22 mmol) were added, and the reaction was removed from the ice bath and the resulting suspension was stirred for 20 h with a vent to an oil bubbler. After this time, the pale yellow solution was cooled on ice, then pyridine (4.04 ml, 50.0 mmol) and 3-nitroaniline (3.00 g, 21.7 mmol) were added. The reaction was then removed from the ice bath, and a water condenser was attached to the flask. The reaction was heated in an oil bath at 45 °C, and after 1 h LC-MS analysis showed the reaction to be complete. The reaction was diluted with ethyl acetate (250 mL) and 1 M aq. HCI (100 mL), then the layers were separated and the organic phase was washed again with aq. HCI, then twice with half-saturated aq. NaHCO3, then brine. The organics were dried over Na2SO4, filtered, and concentrated to a yellow solid, which was dried and pulverized several times, yielding the title compound (6.89 g, 99%).1H NMR (300 MHz, CDCl3): δ8.49 (s, 1H), 8.19-7.85 (m, 3H), 7.67 (app t, J = 6.8 Hz, 2H), 7.57 (app t, J = 8.2 Hz, 1 H), 7.45 (app t, J = 7.4 Hz, 2H). MS (ESI⁺) (M + H): 321.01.
[0542]
[0543] 2-bromo- / V-(3-aminophenyl)benzamide (167)
[0544] 2-Bromo- / V-(3-nitrophenyl)benzamide (6.89 g, 21.5 mmol) was added to a 1 L flask with stir bar and dissolved with THF (143 mL). Sodium dithionite (37.4 g, 215 mmol) was added to a separate flask and dissolved with water (143 mL). The resulting cloudy solution was added to the solution of substrate, and the flask was sealed and flushed with nitrogen, then stirred vigorously for 16 h with a vent line to an oil bubbler. After this time LC-MS analysis showed complete conversion to a mixture of the desired product plus its / V-sulfate. To hydrolyze the sulfated material, saturated aq. ammonium chloride (30 mL) was added, and the mixture was refluxed for 4 h. The layers were then separated, and the aqueous layer was extracted twice with ethyl acetate. The combined organics were washed with brine, then dried over Na2SO4, filtered, and concentrated. The crude material was then dissolved with dichloromethane and ethyl acetate, leaving an insoluble gum behind. The solution was purified by column chromatography (EtOAc / hexanes gradient), to yield the title compound as a pale yellow solid (4.10 g, 66%), which was used without further purification in the subsequent reaction. MS (ESI⁺) (M + H): 291.96.ATTORNEY DOCKET NO: 51861-002W02
[0545]
[0546] 2-bromo- / V-(3-(3-methylbutanamido)phenyl)benzamide (3)
[0547] / V-(3-Aminophenyl)-2-bromobenzamide (50 mg, 0.17 mmol), dichloromethane (1.7 mL), pyridine (17 pL, 0.21 mmol), and isovaleryl chloride (25 pL, 0.21 mmol) were added to a vial with stir bar and stirred for 20 h. The reaction was then diluted with ethyl acetate, then the combined organics were washed with 1 M aq. HCI, then half-saturated aq. NaHCO3, then brine. The crude solution was dried over Na2SO4, filtered, and concentrated to a colorless oil, then purified by column chromatography (EtOAc / hexanes gradient) after dry-loading on SiO2. The title compound was obtained as a white solid (53 mg, 82%).1H NMR (300 MHz, DMSO) 6 10.57-10.40 (s, 1H), 9.91 (s, 1H), 8.07 (s, 1H), 7.71 (dd, J = 0.9, 7.8, 1H), 7.58-7.45 (m, 2H), 7.40 (m, 2H), 7.32 (dm, J = 8.5, 1H), 7.23 (app t, J = 8.0, 1H), 2.19 (d, J = 6.8, 2H), 2.14 - 1.98 (sept, J = 6.5 Hz, 1 H), 0.95 (d, J = 6.5 Hz, 6H). HRMS (ESI⁺): calculated mass for C18H20BrN2O2[M+H] 375.0708, found 375.0697.
[0548] Scheme 8. Synthesis of compound 45.
[0549]
[0550] / V-(3-nitrophenyl)-1,3-oxazole-carboxamide (168)
[0551] To a round bottom flask with a stir bar under nitrogen were added oxazole-5-carboxylic acid and anhydrous DCM / DMF (85:15; 0.2-0.6 M). 3-nitroaniline (1.2 eq.), HOBt (1.2 eq.), EDC-HCI (1.2 eq.), and DIPEA (2.1 eq.) were added and the reaction was stirred under nitrogen. The reaction was diluted with DCM, washed with sat. aq. NaHCO3, brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give crude product. The crude material was loaded onto a 100 g silica gel column and purified via flash chromatography (EtOAc:hexanes 0-100%) to give / V-(3-nitrophenyl)-1,3-oxazole-carboxamide as a yellow solid (40%). LC-MS tR = 5.94 min; m / z = 231.90 (M - H).
[0552]
[0553] / V-(3-aminophenyl)-1,3-oxazole-5-carboxamide (169)
[0554] To a high-pressure hydrogenator flask was added / V-(3-nitrophenyl)-1,3-oxazole-carboxamide (240 mg, 1.03 mmol) and a magnetic stir bar. The starting material was dissolved in methanol (40 mL) and then flushed with nitrogen gas for 5 minutes. Under nitrogen was added Pd / C (10%, 56.0 mg, 0.0526 mmol) and then the vessel was sealed shut. The reaction flask was evacuated and then gassed and degassed with hydrogen three times. The reaction was stirred at room temperature at 15 bar for 1 hour. The reaction mixture was then passed through a silica plug and concentrated to yield / V-(3-aminophenyl)-ATTORNEY DOCKET NO: 51861-002W02
[0555] 1,3-oxazole-5-carboxamide (187 mg, 89%) as an off-white solid. LC-MS tR = 1.46 min; m / z = 203.65 (M + H).
[0556]
[0557] / V-[3-(2-bromobenzamido)phenyl]-1,3-oxazole-5-carboxamide (45)
[0558] To a round bottom flask with a stir bar under nitrogen were added 2-Bromobenzoic acid and anhydrous DCM / DMF (85:15; 0.2-0.6 M). / V-(3-aminophenyl)-1,3-oxazole-5-carboxamide (1.2 eq.), HOBt (1.2 eq.), EDC-HCI (1.2 eq.), and DIPEA (2.1 eq.) were added and the reaction was stirred under nitrogen. The reaction was diluted with DCM, washed with sat. aq. NaHCO3, brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give crude product. The crude material was loaded onto a 10 g silica gel column and purified via flash chromatography (MeOH: DCM 0-8%) to give / V-[3-(2-bromobenzamido)phenyl]-1,3-oxazole-5-carboxamide as a clear yellow oil (60%). LC-MS tR= 4.29 min; m / z = 387.29 (M + H).
[0559] Other Embodiments
[0560] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
[0561] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the invention that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.
[0562] Other embodiments are within the claims.
Claims
ATTORNEY DOCKET NO: 51861-002W02CLAIMS1. A method of treating pain in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound that binds protease-activated receptor 1 (PAR1) and increases β-arrestin activity.
2. The method of claim 1, wherein the pain is neuropathic pain.
3. The method of claim 2, wherein the neuropathic pain is from physical injury.
4. The method of claim 2, wherein the neuropathic pain is a result of diabetic neuropathy.
5. The method of claim 2, wherein the neuropathic pain is a result of chemotherapy-induced peripheral neuropathy (CIPN).
6. The method of claim 1, wherein the pain is inflammatory pain.
7. The method of claim 6, wherein the inflammatory pain is from physical injury or surgery.
8. The method of any one of claims 1 -7, wherein the pain is chronic pain.
9. The method of any one of claims 1 -7, wherein the pain is acute pain.
10. The method of any one of claims 1 -9, wherein the patient is diagnosed as having a neurological disease.
11. The method of claim 10, wherein the neurological disease is selected from ischemic stroke, traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS, " Lou Gehrig's disease"), Parkinson's disease (PD), Huntington's disease (HD), Peri ventricular leukomalacia (PVL), Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, multi-infarct dementia, Pick's disease, primary lateral sclerosis, degenerative ataxias, spinal and spinobulbar muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, multisystem degeneration (Shy-Drager syndrome), familial dysautonomia (Riley-Day syndrome), subacute sclerosing panencephalitis, Sandhoff disease, cortical basal degeneration, primary progressive aphasia, familial spastic disease, Binswanger's disease, dementia (including all underlying etiologies of dementia), fibromyalgia (FM), post-herpetic neuralgia (PHN), trigeminal neuralgia (TGN), anesthesia dolorosa (AD), central pain due to multiple sclerosis (MS), focal nerve injury, peripheral nerve injury, and a neurological condition resulting from surgery or physical injury.ATTORNEY DOCKET NO: 51861-002W0212. The method of claim 11, wherein the neurological disease is selected from ischemic stroke, traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), and a neurological condition resulting from surgery or physical injury.
13. A method of treating a neurological disease in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound that binds PAR1 and increases β-arrestin activity.
14. A method of slowing progression of a neurological disease in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound that binds PAR1 and increases β-arrestin activity.
15. The method of claim 13 or 14, wherein the neurological disease is selected from ischemic stroke, traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Peri ventricular leukomalacia (PVL), Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, multi-infarct dementia, Pick's disease, primary lateral sclerosis, degenerative ataxias, spinal and spinobulbar muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, multisystem degeneration (Shy-Drager syndrome), familial dysautonomia (Riley-Day syndrome), subacute sclerosing panencephalitis, Sandhoff disease, cortical basal degeneration, primary progressive aphasia, familial spastic disease, Binswanger's disease, dementia (including all underlying etiologies of dementia), fibromyalgia (FM), post-herpetic neuralgia (PHN), trigeminal neuralgia (TGN), anesthesia dolorosa (AD), central pain due to multiple sclerosis (MS), focal nerve injury, peripheral nerve injury, and a neurological condition resulting from surgery or physical injury.
16. The method of claim 15, wherein the neurological disease is selected from ischemic stroke, traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), and a neurological condition resulting from surgery or physical injury.
17. The method of any one of claims 1 -16, wherein the compound is a parmodulin.
18. The method of any one of claims 1-17, wherein the compound inhibits PAR1 -mediated Gq protein signaling.
19. The method of any one of claims 1-18, wherein the compound exhibits PAR1 agonist activity.
20. The method of any one of claims 1-18, wherein the compound does not exhibit PAR1 agonist activity.ATTORNEY DOCKET NO: 51861-002W0221. The method of any one of claims 1 -20, wherein following administration of the compound to the patient, the patient exhibits a reduction in pain relative to a measurement of the patient’s pain obtained prior to administration of the compound.
22. The method of any one of claims 1 -20, wherein following administration of the compound to the patient, the patient exhibits a reduction in pain relative to a measurement of pain experienced by a subject of similar age, body mass index, and disease state, but to whom the compound has not been administered.
23. The method of claim 21 or 22, wherein the reduction in pain is assessed by way of the Numerical Rating Scale (NRS), the Neuropathic Scale (NPS), or the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
24. The method of any one of claims 1 -23, wherein following administration of the compound to the patient, the patient experiences an increase in the time period during which the patient retains functional independence, optionally wherein the increase is assessed by way of the Barthel Index (Bl), the modified Rankin Scale (mRS), or the Functional Independence Measure (FIM).
25. The method of any one of claims 17-24, wherein the parmodulin is a compound represented by any one of Formulae (l-IV):wherein each R1and R2is independently selected from the group consisting of absent, hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl;each X1, X2, and X3is independently selected from the group consisting of a covalent bond, -[C(R10)(R11)] -, -S-, -O-C(R12)=C(R13)-, -C(OR15)(R14)-, -N(R16)-, and -C(O)-; wherein v is 0, 1, 2, or 3; each R10, R11, R12, R13, and R14is independently selected from the group consisting of covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the groupATTORNEY DOCKET NO: 51861-002W02consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R11, R12, R13, R14, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;X4is selected from the group consisting of -N(R15)-, -C(O)-, -C(OR16)-, -C(R10)-, and -C(R11)=C(R12)-;each X5and X6is independently selected from the group consisting of a covalent bond, -NR15-, -O-, and -CR16R10-;each G1and G2is independently selected from the group consisting of absent, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; andt is 0, 1, 2, or 3,or a pharmaceutically acceptable salt thereof.
26. The method of claim 25, wherein ring A is selected from the group consisting of:wherein each R100, R101, and R102is independently selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionallyATTORNEY DOCKET NO: 51861-002W02substituted heterocycloalkyl, wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
27. The method of claim 25 or 26, wherein R1is selected from the group consisting of hydrogen and CH3.
28. The method of claim 27, wherein R1is hydrogen.
29. The method of any one of claims 25-28, wherein R2is selected from the group consisting of hydrogen and CH3.
30. The method of claim 29, wherein R2is hydrogen.
31. The method of any one of claims 25-30, wherein G1is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
32. The method of any one of claims 25-31, wherein G1is selected from the group consisting of:wherein each X7and X8is independently selected from the group consisting from O, S, and NH; R100is selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.ATTORNEY DOCKET NO: 51861-002W0233. The method of any one of claims 25-32, wherein G2is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
34. The method of any one of claims 25-33, wherein G2is selected from the group consisting of:wherein each R100and R101is independently selected from the group consisting of hydrogen, OH, NH2, halogen, optionally substituted OR103a, optionally substituted NHR103a, optionally substituted NR103aR103b, optionally substituted SR103a, optionally substituted S(O2)R103a, C(O)OH, C(O)OR103a, C(O)NH2, C(O)NR103aR103b, C(O)NHR103a, CF3, CN, NO2, N3, OCF3, NHC(O)R103a, C(O)R103a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R103aand R103bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
35. The method of any one of claims 25-34, wherein A and G2are optionally substituted aromatic groups.
36. The method of any one of claims 25-34, wherein G2is optionally substituted aliphatic or optionally substituted alkyl.
37. The method of any one of claims 25-34, wherein G2is optionally substituted aryl or optionally substituted heteroaryl.
38. The method of any one of claims 17-24, wherein the parmodulin is a compound represented by Formula (V):wherein each m and y is independently selected from 0, 1, 2, 3, and 4;wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein each R10and R11is independently selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substitutedATTORNEY DOCKET NO: 51861-002W02heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; andwherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,or a pharmaceutically acceptable salt thereof.
39. The method of claim 38, wherein the compound is represented by Formula (VI):wherein each of m and y is independently selected from 0, 1, 2, 3, and 4;wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein each R10and R11is independently selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; andwherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,or a pharmaceutically acceptable salt thereof.
40. The method of claim 39, wherein the compound is represented by Formula (VII):wherein y is selected from 0, 1, 2, 3, and 4;ATTORNEY DOCKET NO: 51861-002W02wherein X5is selected from the group consisting of a covalent bond, -NR15-, and -CR16R10-; wherein R10is selected from the group consisting of a covalent bond, hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; wherein each R15and R16is independently selected from the group consisting of a covalent bond, hydrogen, halogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively two R10, R15, or R16together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring; andwherein G1is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl,or a pharmaceutically acceptable salt thereof.
41. The method of any one of claims 17-24, wherein the parmodulin is a compound represented by Formula (VIII):wherein G5is selected from the group consisting of S(O2)R18, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein R18is optionally substituted alkyl.wherein R1is selected from the group consisting of absent, hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively, G5and R1, or R1and R11, together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;wherein each R10and R11is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;wherein X9is N or O, with the proviso that when X9is O, R1is absent; andwherein each m and y is independently selected from the group consisting of 0, 1, 2, 3, and 4,ATTORNEY DOCKET NO: 51861-002W02or a pharmaceutically acceptable salt thereof.
42. The method of claim 41, wherein the compound is represented by Formula (IX):wherein G5is selected from the group consisting of S(O2)R18, optionally substituted aliphatic, optionally substituted aryl; optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein R18is optionally substituted alkyl.wherein R1is selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; alternatively, G5and R1, or R1and R11, together with the atoms to which they are attached and any intervening atoms may form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;wherein each R10and R11is independently selected from the group consisting of hydrogen, OH, NH2, halogen, OR17a, NHR17a, NR17aR17b, SR17a, S(O)2R17a, C(O)OH, C(O)OR17a, C(O)NH2, C(O)NR17aR17b, C(O)NHR17a, CF3, CN, NO2, N3, OCF3, NHC(O)R17a, C(O)R17a, optionally substituted aliphatic, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; wherein each R17aand R17bis independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; andwherein each m and y is independently selected from the group consisting of 0, 1, 2, 3, and 4, or a pharmaceutically acceptable salt thereof.
43. The method of claim 42, wherein the compound is represented by Formula (X):wherein each R104and R105is independently optionally substituted alkyl; and,R106is a halogen, OCH3, or OR107a; wherein R107ais optionally substituted alkyl,or a pharmaceutically acceptable salt thereof.ATTORNEY DOCKET NO: 51861-002W0244. The method of claim 25 or 41, wherein the compound is selected from the group consisting of compounds 1-156:ATTORNEY DOCKET NO: 51861-002W02ATTORNEY DOCKET NO: 51861-002W02ATTORNEY DOCKET NO: 51861-002W02ATTORNEY DOCKET NO: 51861-002W02or a pharmaceutically acceptable salt thereof.
45. The method of any one of claims 1-44, wherein the compound increases β-arrestin activity by at least 1.1-fold as compared to the level of p-arrestin activity observed in the absence of the compound.ATTORNEY DOCKET NO: 51861-002W0246. The method of claim 45, wherein the compound increases p-arrestin activity by from 1.1 -fold to 50-fold as compared to the level of p-arrestin activity observed in the absence of the compound.
47. The method of any one of claims 1-44, wherein the compound increases p-arrestin activity by about 1.1 -fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.2-fold, 2.4-fold, 2.6-fold, 2.8-fold, 3-fold, 3.2-fold, 3.4-fold, 3.7-fold, 4-fold, 4.4-fold, 4.8-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, 10-fold, 11 -fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, or 50-fold as compared to the level of p-arrestin activity observed in the absence of the compound.
48. The method of any one of claims 1 -47, wherein the compound exhibits an EC₅₀ of less than or equal to 10 μM in an assay that measures PAR1-mediated β-arrestin signaling.
49. The method of claim 48, wherein the compound exhibits an EC₅₀ of less than or equal to 10 μM and an EC₅₀ of greater than or equal to 100 nM in an assay that measures PAR1-mediated β-arrestin signaling.
50. The method of any one of claims 1-49, wherein the compound exhibits an ECso of greater than or equal to 100 pM in an assay that measures PAR2-mediated p-arrestin signaling.
51. The method of claim 50, wherein the compound exhibits an ECso of greater than or equal to 100 pM and an ECso of less than or equal to 900 pM in an assay that measures PAR2-mediated p-arrestin signaling.
52. The method of any one of claims 1 -51, wherein the compound exhibits oral bioavailability.
53. The method of any one of claims 1 -52, wherein upon administration of the compound to a subject, the compound improves the integrity of a subject’s blood brain barrier (BBB), blood-spinal cord barrier (BSCB), or blood-nerve barriers (BNBs).
54. The method of any one of claims 1 -53, wherein upon administration of the compound to a test subject, the compound attenuates pain response as measured by way of a formalin test, hot plate test, tail flick test, Hargreave’s test, acetone test, sensitivity to von Frey filaments, gait analysis, burrowing behavior analysis, and / or Randall-Selitto test.
55. The method of any one of claims 1 -54, wherein upon administration of the compound to a test subject, the compound inhibits endothelial cell retraction.
56. The method of any one of claims 1 -55, wherein a therapeutically effective amount of the compound is administered to the subject orally.ATTORNEY DOCKET NO: 51861-002W0257. A kit comprising: (i) a compound that binds PAR1 and increases p-arrestin activity, and (ii) a package insert, wherein the package insert instructs a user of the kit to administer the compound to a patient in accordance with the method of any one of claims 1-56.
58. The kit of claim 57, wherein the patient is suffering from pain.
59. The kit of claim 58, wherein the pain is neuropathic pain.
60. The kit of claim 59, wherein the neuropathic pain is from physical injury.
61. The kit of claim 59, wherein the neuropathic pain is a result of diabetic neuropathy.
62. The kit of claim 59, wherein the neuropathic pain is a result of chemotherapy-induced peripheral neuropathy (CIPN).
63. The kit of claim 58, wherein the pain is inflammatory pain.
64. The kit of claim 63, wherein the inflammatory pain is from physical injury.
65. The kit of any one of claims 58-64, wherein the pain is chronic pain.
66. The kit of any one of claims 58-64, wherein the pain is acute pain.
67. The kit of any one of claims 58-66, wherein the pain is a result of a neurological disease.
68. The kit of any one of claims 57-67, wherein the compound is a parmodulin;or a pharmaceutically acceptable salt thereof.
69. The kit of any one of claims 57-68, wherein the patient is diagnosed as having a neurological disease selected from traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Peri ventricular leukomalacia (PVL), Friedrich's Ataxia, Wilson's disease, multiple sclerosis, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, multiinfarct dementia, Pick's disease, primary lateral sclerosis, degenerative ataxias, spinal and spinobulbar muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, multisystem degeneration (Shy-Drager syndrome), familial dysautonomia (Riley-Day syndrome), subacute sclerosing panencephalitis, Sandhoff disease, cortical basal degeneration, primary progressive aphasia, familial spastic disease, Binswanger's disease, dementia (including any underlying etiology of dementia), and a neurological condition resulting from surgery or physical injury.ATTORNEY DOCKET NO: 51861-002W0270. The kit of claim 69, wherein the patient is diagnosed as having a neurological disease selected from traumatic brain injury (TBI), diabetic neuropathy, chemotherapy-induced neuropathy, Alzheimer's disease (AD), and a neurological condition resulting from surgery or physical injury.
